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71 
SOME MSM BLOOD DONORS MOVE 
FROM A LIFETIME 
DEFERRAL TO A ONE-YEAR BAN . . .  
“FINALLY” OR “NOT GOOD 
ENOUGH?”* 
HEATHER PRINTZ** 
INTRODUCTION 
It feels good to give.1  Find the hero in you.2  Blood banks choose these 
words carefully to inspire people to donate.  The language is intended to create a 
desire to give and for good reason: every two seconds someone needs blood!3  
But, it also sends an implicit message about heroism and morality; if heroes give 
blood then those who do not must be morally corrupt.4  It’s a logical fallacy, 
especially because some choose not to donate while others are prohibited from 
doing so, but words impact society’s perceptions and opinions.5  This unintended 
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 1. Give Blood, AM. RED CROSS, www.redcrossblood.org/ (last visited Sept. 17, 2015). 
 2. UNITED BLOOD SERVS., www.unitedbloodservices.org/ (last visited Sept. 17, 2015). 
 3. AMERICA’S BLOOD CNTRS. www.americasblood.org/ (last visited Sept. 17, 2015). 
 4. See Craig M. Klugman, Blood Donation and Its Metaphors, 10  AM. J. OF BIOETHICS 46, 46–7 
(2010) (explaining that “[b]y creating a message that it is heroic and moral to donate blood, there is a tacit 
judgment that those who cannot give blood not only are impure, but also that they cannot do the right 
thing”); See also id. at 46 (supporting the idea that the industry has created a metaphor about the 
relationship between donating blood and being moral). 
 5. Id. 
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message creates a feeling of “otherness” or marginalization for those who are 
different, for people who cannot give blood.6  
Blood banks are directed to follow deferral guidelines which, until recently, 
grouped “men who have had sex with another man even one time since 1977” 
(“MSM”) with prostitutes and intravenous drug users as permanently ineligible 
for blood donation, perpetuating a stigma about what it means to be a 
homosexual man.7  In December 2015, the Food and Drug Administration 
(“FDA”) updated its 32-year-old guideline and now recommends blood banks 
“[d]efer for 12 months from the most recent sexual contact, a man who has had 
sex with another man in the past 12 months.”8  Six months earlier, the Supreme 
Court ruled same-sex couples have the right to marry, specifically enumerating 
the ways in which they are equal to heterosexual couples, overturning decades 
of precedent and potentially blazing a trail for lesbian, gay, bisexual, transgender, 
and queer (“LGBTQ”) rights in the courts.9  Yet in its latest guideline, the FDA 
clings to this archaic distinction between MSM and every other sexually active 
blood donor to defer most homosexual men from donating blood, implying: if 
you’re a sexually active homosexual male then you’re probably not a hero. 
The roots of characterization run deep.  In the 1980s, a mysterious epidemic 
swept the nation.10  No one could pinpoint its cause or origin, creating a public 
health crisis but eliciting few ideas for an appropriate response.11  Initially, the 
group of infections later known as Human Immunodeficiency Virus (“HIV”) 
were thought to be transmitted exclusively by men having intercourse with other 
 
 6. See Christopher Fisher & Tony Schonfeld, Sex and Blood: A Deeper Exploration of 
Discrimination in the FDA Blood Donor Policy, 10 AM. J. OF BIOETHICS 40, 40–41 (2010) (describing the 
concept of “otherness”). Memorandum from Dir., Ctr. for Biologics Evaluation & Research, to All 
Registered Blood Establishments, Revised Recommendations for the Prevention of Human 
Immunodeficiency Virus (HIV) Transmission by Blood and Blood Products (Apr. 23, 1992), available at 
http://www.fda.gov/downloads/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/O
therRecommendationsforManufacturers/MemorandumtoBloodEstablishments/UCM062834.pdf  
(providing the exact language of the group in question). 
 7. See Eligibility Criteria by Topic, AM. RED CROSS, http://www.redcrossblood.org/donating-
blood/eligibility-requirements/eligibility-criteria-topic#lifestyle (last visited Sept. 17, 2015) (describing 
who is and is not eligible to donate blood). 
 8. See generally Revised Recommendations for Reducing the Risk of Human Immunodeficiency 
Virus Transmission by Blood and Blood Products, 80 Fed. Reg. 79913 (Dec. 23, 2015) available at 
https://www.gpo.gov/fdsys/pkg/FR-2015-12-23/pdf/2015-32250.pdf. 
 9. See generally Obergefell v. Hodges, 135 S.Ct. 2584 (2015). 
 10. See Christopher McAdam & Logan Parker, An Antiquated Perspective: Lifetime Ban for MSM 
Blood Donations No Longer Global Norm, 16 DEPAUL J. HEALTH CARE L. 21 (2014) (stating the AIDS 
crisis began in the 1980s). 
 11. See Shawn Carroll Casey, Illicit Regulation: A Framework for Challenging the Procedural 
Validity of the “Gay Blood Ban”, 66 FOOD & DRUG L. J. 551, 553 (2011) (stating the origin of AIDS was 
unknown and that it’s arrival created panic); see also Dwayne J. Bensing, Comment, Science or Stigma: 
Potential Challenges to the FDA’s Ban on Gay Blood, 14 U. PA. J. CONST. L. 485, 489 (2011) (stating 
that nothing was known about the disease so authorities lacked an appropriate response). 
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men, though within three years scientists learned the infections were not unique 
to that population or method—HIV could be sexually transmitted or blood-borne 
and affect anyone, regardless of sexual orientation.12  In 1983, the Centers for 
Disease Control and Prevention (“CDC”) informed the public that certain groups 
were at a high risk of transmitting HIV, that no test was available to detect it, and 
suggested high-risk individuals refrain from donating blood, among other 
precautions.13  “Sexually active homosexual or bisexual men with multiple 
partners” were among the groups labeled high-risk.14  The FDA provided the first 
donation guidelines to blood banks as an additional measure to protect the blood 
supply from contamination.15  The guidelines outlining high-risk groups and 
 
 12. See Ryan H. Nelson, An Indirect Challenge to the FDA’s “Gay Blood Ban”, 23 TUL. J. L. & 
SEXUALITY 1, 2 (2011) (stating that AIDS was thought to affect gay men, predominately, if not 
exclusively); see McAdam & Parker, supra note 10, at 23 (stating it was later confirmed that AIDS “was 
both blood-borne and sexually transmitted”); see also Francine A. Hochburg, HIV/AIDS and Blood 
Donation Policies: A Comparative Study of Public Health Policies and Individual Rights Norms, 12 DUKE 
J. COMP. & INT’L L. 231 (2002) (explaining that HIV is the acronym for human immunodeficiency virus 
and the end-stage disease is AIDS or acquired immune deficiency syndrome). 
 13. See CDC, Current Trends Prevention of Acquired Immune Deficiency Syndrome (AIDS): Rep. of 
Inter-Agency Recommendations, 32(8) Morbidity & Mortality Wkly Rep. 101, 101–03 (Mar. 4, 1983), 
available at http://www.cdc.gov/mmwr/preview/mmwrhtml/00001257.htm; see Casey, supra note 11, at 
555 (reiterating that the guideline was not mandatory); McAdam & Parker, supra note 10, at 25 
(explaining that U.S. Public Health Service (“PHS”) “is housed under the Department of Health and 
Human Services (“HHS”)”); Casey, supra note 11, at 561 (explaining the “PHS includes the CDC, 
National Institutes for Health (NIH) and FDA”); Whitney Larkin, Comment, Discriminatory Policy: 
Denying Gay Men the Opportunity to Donate Blood, 11 HOUS. J. HEALTH L. & POL’Y 121, 132 (2011) 
(explaining the FDA has “regulatory jurisdiction over blood, bodily organs, tissue, and fluids”); Hochburg, 
supra note 12, at 243 n.64 (explaining the CDC “has no direct regulatory power. It provides epidemiologic 
information and technical support to other regulatory agencies and information to medical providers and 
the public, but relies on the FDA and other PHS agencies to implement its recommendations.”); McAdam 
& Parker, supra note 10 at 26 (explaining the Center for Biologics Evaluation and Research (“CBER”) is 
“[a] subdivision of the FDA, […and is] is entrusted with drafting regulations to ensure the quality and 
safety of the nation’s blood supply.  Together, the FDA and CBER are charged with licensing blood 
banks.”); Bensing, supra note 11, at 493–94 n.62 (explaining that Blood Products Advisory Committee 
(“BPAC”) is “a standing advisory committee to […] [CBER], […] charged with ‘review[ing] and 
evaluat[ing] data concerning the safety, effectiveness, and appropriate use of blood, products. . .intended 
for use in the diagnosis, prevention, or treatment of human diseases.’… [and] advises the [FDA] 
Commissioner […] ‘of its findings regarding the safety, effectiveness, screening and testing (to determine 
eligibility) of donors. . .and on the quality and relevance of FDA’s research program which provides the 
scientific support for regulating [blood products].’”); Vianca Diaz, Comment, A Time For Change: Why 
the MSM Lifetime Deferral Policy Should Be Amended, 13 U. MD. L.J. RACE, RELIGION, GENDER, & 
CLASS 134, 139 (2013) (explaining the Advisory Committee on Blood and Tissue Safety and Availability 
(“ACBTSA”) “[h]as the authority […] to advise, assist, consult with, and make policy recommendations 
to the Secretary and the Assistant Secretary for Health regarding . . . broad public health, ethical and legal 
issues related to transfusion and transplantation safety”). 
 14. CDC, Current Trends Prevention of Acquired Immune Deficiency Syndrome (AIDS): Rep. of 
Inter-Agency Recommendations, 32(8) Morbidity & Mortality Wkly Rep. 101, 101–03 (Mar. 4, 1983), 
available at http://www.cdc.gov/mmwr/preview/mmwrhtml/00001257.htm. 
 15. See Casey, supra note 11, at 555 (stating that the FDA issued implementation guidelines); Mem. 
from John C. Petricciani, Nat’l Ctr. For Drugs & Biologics, FDA, to All Establishments Collecting Human 
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their relevant deferral periods have been amended several times.16  From 1992 to 
2015, the official policy provided for a permanent blood donation deferral for 
“men who have had sex with another man even one time since 1977.”17 
Since the original guidelines were published, the medical community has 
gained a better understanding of HIV and AIDS.18  First, it is common knowledge 
that neither are exclusive to the homosexual population or contracted only 
through intercourse.19  Second, several tests are now available to determine if 
blood is infected with HIV.20  Additionally, the FDA has enacted a multitude of 
requirements for blood bank licensing, including suitability of donor standards 
in 1984 and the requirement that all blood donations be tested for an extensive 
panel of blood-borne diseases in 1988.21 
There has also been significant social progress, including both a 
diminishing stigma and movement toward legally recognizing a higher form of 
protection for members of the LGBTQ community.22  For these reasons, 
advocates have repeatedly pressed for a revision to the lifetime ban imposed on 
 
Blood for Transfusion (Mar. 24, 1983) (on file with the author) (“advising all establishments collecting 
blood for transfusion to institute additional measures designed to decrease blood collection from 
individual donors and donor groups known to be at an increased risk for transmitting AIDS”). 
 16. See Michael Christian Belli, The Constitutionality of the “Men Who Have Sex with Men” Blood 
Donor Exclusion Policy, 4 J. L. SOC’Y 315, 339 (2003); id. at 339–42 (for a detailed explanation of 
revisions by year). 
 17. See generally Memorandum from Dir., Ctr. for Biologics Evaluation & Research to All 
Registered Blood Establishments, Revised Recommendations for the Prevention of Human 
Immunodeficiency Virus (HIV) Transmission by Blood and Blood Products (Apr. 23, 1992), available at 
http://www.fda.gov/downloads/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/O
therRecommendationsforManufacturers/MemorandumtoBloodEstablishments/UCM062834.pdf; see 
McAdam & Parker, supra note 10, at 27 (stating the MSM lifetime deferral policy became mandatory in 
1992). 
 18. See infra Part III, C.  
 19. See McAdam & Parker, supra note 10, at 23 (stating it was later confirmed sexual orientation 
was not incident to the disease). 
 20. Id. at 29–30 (discussing the various tests that have been developed to detect AIDS). 
 21. John G. Culhane, Bad Science, Worse Policy: The Exclusion of Gay Males from Donor Pools, 24 
ST. LOUIS U. PUB. L. REVIEW 129, 132–33 (2005) (explaining that “[b]lood and other bodily organs, 
tissue, and fluids come within the regulatory jurisdiction of the FDA. Because the FDA is charged with 
licensing blood banks, it is responsible for creating safeguards to minimize the risk that blood infected 
with infectious diseases, such as HIV, will find its way into a recipient body. To that end, the FDA has 
established a battery of requirements relating to the licensing of blood banks, the testing of blood prior to 
its release, and - with particular relevance here - the eligibility of donors.”); see McAdam & Parker, supra 
note 10, at 26 (stating “FDA requires blood donation centers to evaluate individuals prior to testing based 
on medical, social, and sexual history”); see generally 21 C.F.R. § 640.5 (1988) (“Testing the blood”); 
see generally 21 C.F.R. § 640.3 (1984) (“Suitability of donor”). 
 22. McAdam & Parker, supra note 10, at 51, 54–55 (attributing “time and activism” to the new 
perception of gay community then pointing to anti-discrimination laws, same sex marriage, and ethical 
considerations regarding treatment of MSM). 
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MSM, suggesting the deferral was unnecessary and discriminatory.23  The policy 
discriminated against MSM because it did not align their deferral period with 
other high-risk groups or defer other groups who engage in risky behavior, 
perpetuating the false belief of a unique link between homosexual men and 
HIV.24  Driven by fear, ignorance, and a lack of scientific knowledge, initial 
blood donation policy was unquestionably discriminatory, but as science and 
social understanding progressed it should have been revised.25  Despite social 
and scientific advancements, the FDA has not amended the blood donation 
policy for MSM until now.26 
In December 2014, the FDA announced it would recommend a change to 
the MSM lifetime deferral in favor of a one-year deferral, allowing men who 
have abstained from sex with another man for one year to donate blood.27  The 
agency noted it considered the revision in light of scientific evidence supporting 
the safety of doing so but did not address the past or continued discriminatory 
impact.28  In May 2015, it provided a draft of the guidelines for notice and 
comment and in December, handed down final guidance on the matter.29 
At first blush, the revision appears to address what advocates have been 
calling for.  Yet most consider the policy change an insufficient gesture that does 
 
 23. See Nelson, supra note 12, at 2 (noting some advocates have called for a complete rescission of 
the ban and others seek a less harsh policy); see Diaz, supra note 12, at 140 (providing the blood banks 
position that the “current lifetime deferral for [MSM] is medically and scientifically unwarranted and 
should be modified.”); see Alissa Scheller & Anna Almendrala, Why Even a 12-Month Ban on Blood 
Donations From Gay Men Makes No Sense, HUFFPOST, (Dec. 23, 2014, 9:33 PM), 
http://www.huffingtonpost.com/2014/12/23/gay-blood-ban-deferral_n_6374374.html (quoting Dr. 
William Kobler, spokesman for the American Medical Association, “[t]he lifetime ban on blood donation 
for men who have sex with men is discriminatory and not based on sound science.”). 
 24. Diaz, supra note 12, at 135, 137 (explaining the unconstitutional and stigmatizing implications 
of the ban). 
 25. See McAdam & Parker, supra note 10, at 30–31 (explaining that “many countries recognize 
deferral policies were enacted during time of confusion, stigma, and limited science” and their bans have 
been reconsidered in light of scientific and social progress); Id. at 23 (stating many policies were guided 
by fear and ignorance). 
 26. See Belli, supra note 16 at 338.  
 27. Food & Drug Admin., FDA Comm’r Margaret A. Hamburg’s Statement on FDA’s Blood Donor 
Deferral Policy for Men Who Have Sex with Men (Dec. 23, 2014), available at 
http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm427843.htm  
 28. Id.; see Dominic Holden, FDA Recommends Relaxing Ban On Gay Men Donating Blood-With a 
Big Caveat, BUZZFEED, (Dec. 23, 2014, 12:55 PM), http://www.buzzfeed.com/dominicholden/fda-
recommends-relaxing-ban-on-gay-men-donating-blood-with-a#.wk8pzp4gZ (providing statements from 
several advocacy groups that call the revision just as discriminatory). 
 29. See generally Revised Recommendations for Reducing the Risk of Human Immunodeficiency 
Virus Transmission by Blood and Blood Products, 80 Fed. Reg. 27973 (proposed May 15, 2015), 
available at http://www.gpo.gov/fdsys/pkg/FR-2015-05-15/pdf/2015-11690.pdf; see generally Revised 
Recommendations for Reducing the Risk of Human Immunodeficiency Virus Transmission by Blood and 
Blood Products, 80 Fed. Reg. 79913 (Dec. 23, 2015) available at https://www.gpo.gov/fdsys/pkg/FR-
2015-12-23/pdf/2015-32250.pdf. 
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not address the heart of the issue: the continued stigma and irrational 
discrimination against MSM.  Facially, the revised ban allows more MSM to 
donate but in practice it continues to prevent most from doing so, based solely 
on sexual orientation.30  From the first suggestions that HIV was uniquely or 
particularly related to male homosexuality, advocates have advanced public 
policy, scientific, administrative, and constitutional arguments against singling 
out the group and later against the lifetime deferral.31  In light of the revised 
deferral, this Comment departs slightly from those paths and argues that the 
revision maintains the same discriminatory effect by going against notions of 
administrative constitutionalism, equal protection, and principles of bioethics.  
This Comment further argues that the revision does not effectively reflect 
scientific advancements, that science does not support singling out MSM as a 
category, and that the relevant science does not exist in a vacuum but must 
consider the social impact. 
Part I describes the evolution of HIV/AIDS and the prohibition on MSM 
blood donation.32  Part II describes previous attempts to revise the ban, the 
contours of the revision, and some defenses and reactions to the FDA’s proposal 
and final guidance.33  Part III argues that the FDA has an obligation to interpret 
its guidelines in tune with standard constitutional interpretations, that the 
direction of constitutional jurisprudence with respect to members of the LGBTQ 
community has been racing toward elevated scrutiny so the policy could soon 
face a potentially fatal constitutional challenge, and that despite scientific 
support for a one-year deferral over a lifetime ban, the use of MSM as a category 
is not supported by science.34 
I. EVOLUTION OF BLOOD DONATION GUIDELINES IN THE CONTEXT OF HIV 
The obscure infections later known as HIV were identified in 1980.35  
Between October 1980 and May 1981, five otherwise healthy, homosexual men 
in Los Angeles were treated for pneumocystis carinii pneumonia—a rare lung 
infection.36  On June 5, 1981, the CDC described these cases in the Morbidity 
 
 30. See Holden, supra note 28 (outlining some critics unfavorable response to the proposed revision); 
id. (quoting Gay Men’s Health Crisis which explained the revision functioned as de facto lifetime ban). 
 31. E.g., Diaz, supra note 12; E.g., McAdam & Parker, supra note 10. 
 32. See infra Part I. 
 33. See infra Part II. 
 34. See infra Part III. 
 35. Matthew L. Morrison, Comment, Bad Blood: An Examination of the Constitutional Deficiencies 
of the FDA’s ‘Gay Blood Ban’, 99 MINN. L. REV. 2363, 2366 (2015). 
 36. McAdam & Parker, supra note 10, at 22; see Diaz, supra note 12, at 136 (explaining the men 
were from Los Angeles). 
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and Mortality Weekly Report, becoming the first record of the future epidemic.37  
The following month, the CDC reported that twenty-six homosexual men in 
California and New York developed Kaposi’s sarcoma (another rare infection).38  
Soon, doctors across the country began to disclose similar “opportunistic 
infections,” and reported 270 cases of these infections by the end of 1981.39 
That same year, the CDC studied 116 homosexual men with similar 
infections and found most had multiple sexual partners.40  This information, and 
the knowledge that only homosexual men had developed these infections, led to 
speculation that the infections were either caused by a sexually transmitted 
disease which caused a repeated infection and breakdown of the immune system 
or that they were an immune suppressant effect caused by overexposure to many 
different sources of sperm.41  Some reasoned the disease must be linked to a 
homosexual lifestyle or sexual orientation.42  The infections were referred to as 
the “gay plague, gay cancer, and gay-related immune disorder,” leading people 
to associate having HIV with being homosexual.43   
Early the following year, an elderly hemophiliac patient contracted the 
same rare pneumonia, a condition his physician believed came from receiving 
contaminated clotting factor during a blood transfusion.44  Up to that point, 
scientists only suspected the “opportunistic infections” could be spread through 
 
 37. Diaz, supra note 12, at 136; see also About the Morbidity & Mortality Wkly Rep. (MMWR) Series, 
CDC.GOV, http://www/cdc.gov/mmwr/about.html (describing the MMWR series as “the agency’s primary 
vehicle for scientific publication of timely, reliable, authoritative, accurate, objective, and useful public 
health information and recommendations”). 
 38. McAdam & Parker, supra note 10, at 22 (citing CDC, Kaposi’s Sarcoma and Pneumocystis 
Pneumonia Among Homosexual Men—New York City and California, 30 Morbidity & Mortality Wkly 
Rep. 1 (July 3, 1981)). 
 39. Diaz, supra note 12, at 136; see Larkin, supra note 12, at 133 (defining opportunistic infections 
as “infections in people, caused by organisms that don’t usually cause disease in people with a healthy 
immune system.”); see also  Belli, supra note 16, at 328–31 (discussing the pathology of HIV/AIDS in 
greater detail). 
 40. Larkin, supra note 12, at 133; id. at 134 (stating that each of the men in the study “had an average 
of 1,100 sexual encounters”). 
 41. See Belli, supra note 16, at 329 (stating homosexual men formed the initial population in which 
AIDS occurred); see Larkin, supra note 12, at 134 (describing speculation about what caused the 
infections). 
 42. McAdam & Parker, supra note 10, at 23. 
 43. Id.; see Diaz, supra note 12, at 137 (noting that because most cases of AIDS were homosexual 
men, a stigmatization was attached to that group). 
 44. See Adam R. Pulver, Comment, Gay Blood Revisionism: A Critical Analysis of Advocacy and 
the “Gay Blood Ban”, 17 L. & SEXUALITY 107, 110–11 (2008) (describing the circumstances of the 
hemophiliac patient); id. (“Factor VIII, a life-prolonging clotting factor derived from thousands of blood 
donors given to hemophiliacs.”); National Hemophilia Foundation, 
https://www.hemophilia.org/Bleeding-Disorders/Types-of-Bleeding-Disorders/Other-Factor-
Deficiencies/Factor-XIII (last visited Nov. 28, 2015) (explaining that Factor VIII is a protein that can be 
added to blood in order to stabilize it). 
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blood.45  Due to the patient’s rapid death, doctors never confirmed the presence 
of HIV, but his was the first unofficial incident linked to a blood transfusion.46  
In July of 1982, the CDC identified three more people with hemophilia and the 
same signs of immune suppression and opportunistic infections.47  The National 
Hemophilia Foundation publicly reassured hemophiliacs that the risk of 
contracting these infections via the blood supply was minimal but behind closed 
doors, the Foundation pressed the blood banks to stop accepting donations from 
homosexual men.48  The blood banks opposed the exclusionary message and 
donation loss.49  As the infections spread beyond the homosexual male 
community, the CDC hosted a meeting to evaluate ways to protect the blood 
supply.50  Meeting attendees discussed providing donor deferral guidelines but 
the National Hemophilia Foundation, the gay community, and the FDA 
independently opposed this idea.51  The meeting ended without resolution, in part 
because only the CDC believed a crisis was imminent.52  In September, it 
 
 45. See id. at 111 (explaining that the CDC feared AIDS could be transmitted via blood transfusion 
as well as through intercourse). 
 46. Id. 
 47. CDC, Epidemiologic Notes and Reports Pneumocystis Carinii Pneumonia among Persons with 
Hemophilia A, 31 Morbidity & Mortality Wkly Rep. 365 (July 16, 1982), available at 
http://www.cdc.gov/mmwr/preview/mmwrhtml/00001126.htm); see generally CDC, Epidemiologic 
Notes and Reports Update on Kaposi’s Sarcoma and Opportunistic Infections in Previously Healthy 
Persons, 31 Morbidity & Mortality Wkly Rep. 294 (June 11, 1982), available at 
http://www.cdc.gov/mmwr/preview/mmwrhtml/00001111.htm (providing detailed statistics and 
characteristics about people infected between June 1, 1981 and May 28, 1982); see McAdam & Parker, 
supra note 10, at 23 (noting that people with these infections also included “intravenous-drug users, 
Haitians, hemophiliacs, and non-homosexual blood transfusion recipients”). 
 48. Ronald Bayer, Blood and AIDS in America Science, Politics, and the Making of an Iatrogenic 
Catastrophe, in BLOOD FEUDS 20, 21 (Eric A. Feldman & Ronald Bayer eds., 1999) (explaining the 
position of the National Hemophilia Foundation); see Hochburg, supra note 12, at 244 (explaining that 
the National Hemophilia Foundation proposed forbidding homosexual men from donating blood). 
 49. See Bayer, supra note 48, at 23 (explaining the blood banks’ position on excluding homosexual 
donors); see Hochburg, supra note 12, at 244 (explaining that the blood banks’ stance on excluding 
homosexual donors). 
 50. See Bensing, supra note 11 at 489 (explaining that a response to the threat to the blood supply 
was necessary); Pulver, supra note 44, at 111 (“Meeting attendees included leaders from the National 
Institutes of Health, [FDA], the blood banking industry, hemophiliac groups, and the National Gay Task 
Force”). 
 51. See id. (“Hemophiliac groups […] were concerned about labeling hemophiliacs with the stigma 
of a ‘gay disease,’ and were also wary that panicked hemophiliacs might stop their Factor VIII treatment.  
The gay community […] arguing that it was “too soon to push for guidelines”, and that the civil rights of 
gays outweighed the inconclusive evidence about the risks of transmission. The FDA itself was also 
unpersuaded of any pressing emergency.”); see Bayer, supra note 48, at 23 (explaining that the blood 
banks felt there was too much scientific uncertainty to support homosexual male donor exclusion). 
 52. See Pulver, supra note 43, at 112 (explaining there was a “wait and see attitude”); Cf. Bayer, 
supra note 48 at 24 (explaining that a decade later, Dr. James Curran, head of AIDS activities at the CDC, 
would reflect that the CDC was aware very early of a link between AIDS and the blood supply due to its 
experience with hepatitis and sexually transmitted diseases but because the CDC had no experience in 
with blood diseases, they were not taken seriously). 
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officially labeled the mystery infections “Acquired Immune Deficiency 
Syndrome” (“AIDS”).53 
The end of the year brought two transmission cases confirming the link 
between AIDS and the blood supply, as well as the realization that AIDS had a 
“carrier state” in which people appeared healthy because the disease had not yet 
manifested itself. 54  This “latency period” meant there was no way to distinguish 
safe donors from asymptomatic carriers.55  Further, no one could determine what 
caused AIDS so it was virtually impossible to create a test to detect it.56 
A week before the next meeting, set for January 1983, the CDC’s director 
of AIDS activities “urged the gay community to seize the ‘political initiative with 
a call for voluntary withdrawal of all gay men from the donor pool . . . The thing, 
is people are dying.  The medical problem is more important than the civil rights 
issue.’ “57  Around the same time, one plasma supplier announced its decision to 
prohibit homosexual men from donation.58  At the meeting, the CDC presented 
evidence related to the risk of AIDS in the blood supply but attendees remained 
unconvinced, believing the data were minimal and inconclusive.59  The CDC 
advanced two options: screen high-risk donors or adopt surrogate testing for 
another marker like hepatitis B, an infection with which approximately 80% of 
AIDS patients were affected.60  The LGBTQ community protested questioning 
donors about sexual orientation and habits, stating it was “blood, not donors, that 
should be subject to scrutiny” and attempted to develop a method of self-
exclusion.61  The blood banking organizations continued to oppose excluding 
 
 53. See  Belli, supra note 16, at 328; CDC, Current Trends Update on Acquired Immune Deficiency 
Syndrome (AIDS)—United States, 31 Morbidity & Mortality Wkly Rep. 507 (Sept. 24, 1982), available 
at http://www.cdc.gov/mmwr/preview/mmwrhtml/00001163.htm (“CDC defines a case of AIDS as a 
disease, at least moderately predictive of a defect in cell-mediated immunity, occurring in a person with 
no known cause for diminished resistance to that disease”). 
 54. Casey, supra note 11, at 553 (noting the first two confirmed transmission cases in December 
1982); Pulver, supra note 44 at 110 (explaining that some individuals may not have symptoms because of 
the latency period between infection and detection while others do not have symptoms because they are 
not carriers but without a test, there was no way to distinguish between the two). 
 55. Casey, supra note 11, at 553 (explaining there was a period of time where the disease could go 
undetected); Pulver, supra note 44, at 110. 
 56. Casey, supra note 11, at 553 (explaining no one knew what caused AIDS). 
 57. See Bayer, supra note 48, at 23; Hochburg, supra note 12, at 244. 
 58. Bayer, supra note 48, at 23. 
 59. See id. (recalling the evidence presented by the CDC and the response of the blood banking 
community); See Pulver, supra note 44, at 112 (recalling the response of the blood banking community); 
Cf. Bayer, supra note 48, at 24 (“A decade later, Curran would note that the CDC’s failure at the meeting 
was rooted in its lack of credibility among blood bankers.”). 
 60. See id. (describing the potential ways to screen donors). 
 61. Id.; See id. at 24–5 (describing the efforts of the gay community). 
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homosexual males entirely but the National Hemophilia Foundation publically 
demanded it.62 
By 1983, over 1,000 cases of AIDS were reported across the country.63  
Blood banks did not support the use of surrogate testing so it seemed the only 
viable course of action was to create an ad hoc screening policy.64  In March, the 
CDC issued the first recommended guidelines for AIDS prevention through 
blood donation, which suggested people at an increased risk of carrying AIDS 
should not donate blood.65  The guideline noted it was intended as an interim 
measure until accurate tests could be devised.66  Three weeks later, the FDA 
released a memorandum to organizations responsible for collecting blood, 
outlining the persons with an increased risk for carrying AIDS, and encouraging 
blood banks to implement measures to reduce the chances of collecting infected 
blood.67 Persons at an increased risk included: “persons with symptoms and signs 
suggestive of AIDS, sexually active homosexual or bisexual men with multiple 
partners, Haitian entrants to the United States, present or past abusers of 
intravenous drugs, and sexual partners of individuals at increased risk for 
AIDS.”68 
 
 62. Id. at 24. 
 63. See McAdam & Parker, supra note 10, at 22. 
 64. See Bayer, supra note 48, at 27–29 (describing the controversy surrounding surrogate testing). 
 65. Casey, supra note 11, at 555; see generally CDC, Current Trends Prevention of Acquired Immune 
Deficiency Syndrome (AIDS): Rep. of Inter-Agency Recommendations, 32(8) Morbidity & Mortality Wkly 
Rep. 101-103 (Mar. 4, 1983), available at http://www.cdc.gov/mmwr/preview/mmwrhtml/00001257.htm 
(“1. Sexual contact should be avoided with persons known or suspected to have AIDS. Members of high-
risk groups should be aware that multiple sexual partners increase the probability of developing AIDS. 2. 
As a temporary measure, members of groups at increased risk for AIDS should refrain from donating 
plasma and/or blood. This recommendation includes all individuals belonging to such groups, even though 
many individuals are at little risk of AIDS [emphasis added]. Centers collecting plasma and/or blood 
should inform potential donors of this recommendation. The Food and Drug Administration (FDA) is 
preparing new recommendations for manufacturers of plasma derivatives and for establishments 
collecting plasma or blood. This is an interim measure [emphasis added] to protect recipients of blood 
products and blood until specific laboratory tests are available. 3. Studies should be conducted to evaluate 
screening procedures for their effectiveness in identifying and excluding plasma and blood with a high 
probability of transmitting AIDS. These procedures should include specific laboratory tests as well as 
careful histories and physical examinations. 4. Physicians should adhere strictly to medical indications for 
transfusions, and autologous blood transfusions are encouraged. 5. Work should continue toward 
development of safer blood products for use by hemophilia patients. The National Hemophilia Foundation 
has made specific recommendations for management of patients with hemophilia”). 
 66. See generally CDC, Current Trends Prevention of Acquired Immune Deficiency Syndrome 
(AIDS): Rep. of Inter-Agency Recommendations, 32(8) Morbidity & Mortality Wkly Rep. 101–03 (Mar. 
4, 1983), available at http://www.cdc.gov/mmwr/preview/mmwrhtml/00001257.htm. 
 67. See McAdam & Parker, supra note 10, at 23 (stating the FDA established regulations); 
Memorandum from John C. Petricciani, M.D., Dir., Office of Biologics, Nat’l Ctr. for Drugs & Biologics, 
FDA, to All Establishments Collecting Human Blood for Transfusion, Recommendations to Decrease the 
Risk of Transmitting Acquired Immune Deficiency Syndrome (AIDS) from Blood Donors 1 (Mar. 24, 
1983). 
 68. Id. 
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The FDA has revised portions of the original memorandum several times.69  
In 1984, the group “sexually active homosexual or bisexual men with multiple 
partners” became “males who have had sex with more than one male since 1979 
and males whose partner has had sex with more than one male since 1979.”70  In 
1990, all high-risk deferral groups underwent similar changes, which prioritized 
risky behavior over status.71  The 1992 memorandum re-labeled the relevant 
high-risk group “men who have had sex with another man since 1977” and 
moved sexual partners of those in all high-risk categories from lifetime deferral 
to a one-year deferral.72  More importantly, the memorandum made clear that 
MSM should not donate blood, a change from earlier guidelines which 
functioned more like a suggestion.73  This is the first time the guidelines were 
considered mandatory, confirming a lifetime deferral for MSM.74 
In 1984 and 1988 respectively, the FDA codified the suitability standards 
for blood donors and the requirement that all blood be tested for infectious 
diseases.75  The former are medical guidelines, intended to protect the health of 
the blood donor, but it is worth noting that this codified statute makes no 
reference to MSM or other high-risk persons, specifically.76 
 
 69. Belli, supra note 16, at 339; see id. at 339–43 (for a detailed explanation of the revisions by year). 
 70. Id. at 339. 
 71. See id. at 340 (stating that “The 1990 memorandum emphasized risky behaviors over status under 
the theory that the former provide a more accurate basis for excluding those at high risk.  The author of 
the memorandum observed, ‘the focus (of communications with potential donors) should be on behavior 
and not on stereotypes (e.g., many men who have had male-to-male sexual experiences do not identify 
themselves as ‘homosexual,’ ‘gay,’ or ‘bisexual’)). 
 72. See McAdam & Parker, supra note 10, at 24; see Belli, supra note 16, at 341. 
 73. See generally Memorandum from Dir., Ctr. for Biologics Evaluation & Research to All 
Registered Blood Establishments, Revised Recommendations for the Prevention of Human 
Immunodeficiency Virus (HIV) Transmission by Blood and Blood Products (Apr. 23, 1992), available at 
http://www.fda.gov/downloads/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/O
therRecommendationsforManufacturers/MemorandumtoBloodEstablishments/UCM062834.pdf. 
 74. See Naomi G. Goldberg, M.P.P. & Gary J. Gates, Ph.D., Effects of Lifting the Blood Donation 
Ban on Men Who Have Sex with Men, 5 PITT. J. ENVTL. PUB. HEALTH L. 49, 51 (2011) (stating that men 
in the MSM category are given a lifetime deferral); see McAdam & Parker, supra note 10, at 27 (stating 
that guidelines are mandatory); but see Casey, supra note 11, at 552 (explaining the argument that because 
the FDA did not follow the proper procedure for enacting a binding regulation, this is technically only a 
guideline. However, under 21 C.F.R. § 640.2, the FDA is in charge of licensing blood centers and could 
revoke licenses of the establishments not in compliance with its directive, although that might be open to 
challenge.  Therefore, this is treated as a mandatory regulation). 
 75. See generally 21 C.F.R. § 640.3 (1984); see generally 21 C.F.R. § 640.5 (1988). 
 76. See Belli, supra note 16, at 322 (explaining that 21 C.F.R § 640.3 are “medical guidelines for 
selecting blood donors”); see Bensing, supra note 11, at 490 (stating the Code of Regulations does not 
specify MSM as high-risk); see Larkin, supra note 12, at 122–24 (describing the blood donation process 
as follows: Blood donors are educated on “risks of infectious diseases transmitted by donating blood.” 
Prospective donors must complete a health history form designed to identify possible exposure “to 
diseases that could taint the blood supply” or whether donating would risk their own health.  If either risk 
is possible, the donor will be deferred. Then the donor is subjected to a mini physical. If they pass, they 
may donate.); see id. at 125 (describing people who may donate: healthy, aged 17, at least 110 pounds, do 
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Between 1983 and 1985, scientists identified three viruses as the probable 
cause of the infections; in 1986, the viruses were grouped and renamed “HIV.”77  
In 1985, the FDA approved the first HIV antibody blood test—an enzyme-linked 
immunosorbent assay (“ELISA”) test that could detect human antibodies 
produced in response to exposure to HIV.78  Two years later, the FDA approved 
the “Western Blot” test to be used in conjunction with the ELISA test.79  
Although using the tests together produced almost 100% effective rate in the 
ability to detect HIV in blood, the combination did not overcome the latency 
problem.80  In the early 2000s, scientists developed a “NAT” or nucleic acid test, 
which uses “primers that identify RNA or DNA in blood samples” and can detect 
an HIV infection in just under two weeks.81 
II.  THE ROAD TO AMENDMENT: CONTOURS AND PERSPECTIVES OF CHANGE 
A. Desperately Seeking Change 
The first major catalyst for a policy revision came in mid-2000, as the 
country faced a critical blood shortage.82  An insufficient blood supply is as much 
a threat as a contaminated one.83  Possibly in consideration of that fact, the Blood 
 
not fall into a deferral category.); see id. at 125–26 (noting that deferral categories speak to “(i) people 
who engage in high risk behavior; (ii) people who have been incarcerated; (iii) people with signs and 
symptoms of HIV; (iv) people who were born, lived in or visited Pattern II countries; and (v) rape victims” 
and that people in high-risk categories include: intravenous drug users, MSM, and prostitutes.); see id. at 
126–7 (explaining the two deferral types, temporary and permanent, noting that permanent deferral is 
required when the donor “has an experience or condition that puts the recipient or donor at a health risk 
as a result of blood donation. The second category is defined by the donor’s behaviors that have put him 
or her at an increased risk for HIV or other serious diseases. And the last category is when a person has 
spent time in a particular geographic area that has a high incidence of HIV or other serious diseases.”); 
see id. at 127 (describing the relevant questions in the health history form as questions about “behavioral 
exclusions that would elevate a donor’s risk for HIV or other diseases transmitted through the blood 
stream. [Such as] whether a potential donor has ever had ‘sexual contact’ with a person with HIV, ever 
been paid for sex or had sex with someone who has paid for sex, or ever had a tattoo [and] behaviors and 
experiences that temporarily or permanently bar blood donation [including:] “From 1977 to present, have 
you [male donors] had sexual contact with another male, even once?”). 
 77. See Belli, supra note 16, at 331–32 (describing that researchers identified which viruses were 
responsible for the epidemic and that they were grouped together and named HIV). 
 78. Id. at 333. 
 79. Id. at  335 (explaining the improvements the “Western Blot” test had over the “ELISA” test). 
 80. Diaz, supra note 12, at 145; see Casey, supra note 11, at 556 (explaining that although a test was 
developed to detect infected blood, the deferral categories were important because of the “latency period”). 
 81. See McAdam & Parker, supra note 10, at 29—30; see Morrison, supra note 35, at 2371. 
 82. Belli, supra note 16, at 317; Id. (explaining that to address the shortage, the Surgeon General 
created Advisory Committee on Blood and Tissues Safety and Availability to encourage blood donors to 
give regularly). 
 83. See Arthur Caplan, Blood Stains-Why an Absurd Policy Banning Gay Men as Blood Donors Has 
Not Been Changed, 10  AM. J. OF BIOETHICS  2 (2010). 
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Products Advisory Committee (“BPAC”) met to review the MSM deferral policy 
that fall. 84  At the meeting, the FDA asked BPAC whether scientific data 
supported a five-year deferral policy.85  The two major blood banks took opposite 
stances on the suggestion; the American Red Cross (“ARC”) stated its opposition 
while the American Association of Blood Banks (“AABB”) offered its support, 
but BPAC voted against recommending an amendment.86  Another six years 
passed before BPAC revisited the issue, holding a meeting in 2006 to collect the 
most current information regarding the safety of amending the policy.87  At that 
meeting, ARC reversed its earlier position, calling the permanent ban “medically 
and scientifically unwarranted,” and at least one FDA official admitted the 
current risks were extremely low, but again, no amendment was made.88  
In February 2010, the advocacy group Gay Men’s Health Crisis reignited 
the debate when it released a report condemning the lifetime deferral in light of 
scientific and societal progress.89  The report stated the policy “reinforce[d] 
incorrect and outdated information about the spread of HIV that serve[d] to 
discriminate against and stigmatize gay and bisexual men” in light of detection 
rates in HIV testing and less restrictive referrals for other groups at an elevated 
risk.90 
The following month, eighteen Senators, including then-Senator John 
Kerry, sent a letter to the Department of Health and Human Services (“HHS”) 
 
 84. Pulver, supra note 44, at 118; see  Belli, supra note 16, at 342–43 (explaining that two reasons 
BPAC met to consider changing the ban were the acceptance of the NAT test, and the FDA’s 
understanding “of blood-bank error rates, their types and frequencies”); see generally U.S. FOOD & DRUG 
ADMIN. BLOOD PRODS. ADVISORY COMM., TRANSCRIPT OF PROCEEDINGS: 67TH MEETING 201–02, 
(2000), available at http://www.fda.gov/ohrms/dockets/ac/00/transcripts/3649t2.rtf. 
 85. Belli, supra note 16, at 343. 
 86. See Pulver, supra note 44, at 118 (stating the American Association of Blood Banks supported 
the change and the American Red Cross opposed); see also  Belli, supra note 16, at 343–348 (describing, 
at length, why the committee did not support the change to a 5-year deferral); but see Pulver, supra note 
44, at 118 (noting that “[a]t the start of the meeting, the committee agreed that the permanent ban on gay 
men seemed discriminatory, lacked a firm foundation in science, and should be changed” and also that 
many groups supported a change in the policy). 
 87. See Goldberg, supra note 74, at 52. 
 88. Id.; see id. (providing that the AABB’s argument any deferral beyond a year was not necessary 
because that was the longest known latency period required to detect HIV and that one year would be 
consistent with other groups at a high-risk due to sexual exposure); see id. (recounting the statement of an 
FDA official who said that the “current risks are now so low that they cannot be measured directly and, 
hence, we rely on models to estimate the current residual risk, that is to say the risk after all the safeguards 
have been followed.”); see Bensing, supra note 11, at 494 (explaining that the committee voted against a 
change); see generally U.S. FOOD & DRUG ADMIN. BLOOD PRODS. ADVISORY COMM., TRANSCRIPT OF 
PROCEEDINGS: 87TH MEETING (2006), available at 
http://www.fda.gov/ohrms/dockets/ac/06/transcripts/2006-4226t1.pdf. 
 89. Diaz, supra note 12, at 138–39. 
 90. See generally Gay Men’s Health Crisis, A Drive for Change: Reforming U.S. Blood Donation 
Policies (Sean Cahill, Nathan Schaefer, & John A. Guidry eds., 2010). 
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demanding reconsideration of the MSM blood donor policy.91  The FDA 
responded with a curt statement, declaring simply that the “ban was based on 
current science and data,” to which former Senator Kerry pushed back, pointing 
out the disparity between high-risk individuals such as prostitutes and sexual 
partners of those with HIV having a one-year deferral and homosexual activity 
burdened with a lifetime deferral, yet no policy at all for unprotected 
heterosexual intercourse.92  Despite the FDA’s dismissive statement, support for 
a revision continued to pour in, so the Advisory Committee on Blood and Tissue 
Safety and Availability (“ACBTSA”) met again in June to reevaluate the ban’s 
social and scientific issues.93  The day before the meeting, forty-three members 
of Congress showed their support for a revision with another letter to HHS, 
echoing ARC’s earlier sentiment in the lack of justification and scientific 
inexactitude in not deferring heterosexuals who engage in unprotected sex while 
permanently deferring “monogamous and married homosexual partners who 
practice safe sex”, and urged the agencies to forsake “blanket deferrals” in favor 
of screening for high-risk behavior.94  The letter went so far as to state that, 
“keeping discriminatory policies on the books, and denying willing donors the 
opportunity to help others, put the integrity of the blood donation system at 
risk.”95 
At the 2010 meeting, AABB, America’s Blood Centers, and ARC 
submitted a joint statement reaffirming their 2006 position that the MSM policy 
was “scientifically unwarranted,” stating it should be revised to parallel the 
policies for other groups with an increased risk of transmitting infections.96  The 
 
 91. Diaz, supra note 12, at 139; see  Casey, supra note 11, at 552 (noting that Congress has pushed 
for change based on “sociological and scientific changes”); see generally Letter from Sen. John Kerry et 
al., U.S. Congress, to the Advisory Comm. on Blood Safety & Availability (Mar. 4, 2010), available at 
http://hemophiliafed.org/uploads/2010/04/Senators-LETTER-TO-FDA-ON-MSM-2-3-4-2010-3.pdf. 
 92. Diaz, supra note 12, at 139; see generally Senators: Lift Ban on Gays Donating Blood, 
CBSNEWS (Mar. 4, 2010, 3:32 PM), http://www.cbsnews.com/news/senators-lift-ban-on-gays-donating-
blood/ (providing portion of FDA response); see generally Sen. John Kerry’s Open Letter to FDA Boss, 
SAN DIEGO GAY & LESBIAN NEWS, (Mar. 10, 2010), http://sdgln.com/health/2010/03/09/sen-john-kerry-
s-open-letter-fda-boss#sthash.XF1Nx38y.dpbs (Sen. Kerry responding the FDA). 
 93. See Diaz, supra note 12, at 139–140 (stating who supported the meeting); see generally 
ADVISORY COMMITTEE ON BLOOD & TISSUE SAFETY, CAPTION NOTES (2010), available at 
http://nih.granicus.com/TranscriptViewer.php?view_id=22&clip_id=45. 
 94. Diaz, supra note 12, at 140; see generally Letter from Sen. John Kerry et al., U.S. Congress, to 
the Advisory Comm. on Blood Safety & Availability (Jun. 9, 2010), available at 
http://farr.house.gov/index.php/press-releases-187/706-june-9-2010-lawmakers-call-for-fda-to-revise-
blood-donation-policy. 
 95. See generally id. 
 96. See Diaz, supra note 12, at 140 (providing the blood banks’ position that the MSM policy was 
“medically and scientifically unwarranted and should be modified and made comparable with criteria for 
other groups at increased risk for sexual transmission of transfusion-transmitted infections.”); see 
generally Am. Ass’n of Blood Banks, Am. Blood Ctrs. & Am. Red Cross, J. Statement Before the 
Advisory Comm. on Blood Safety & Availability: Donor Deferral for Men Who Have Had Sex with 
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blood banks recommended a one-year deferral, but the committee once again 
voted to retain the lifetime ban.97  Although it recognized the policy as 
“suboptimal” then, the committee declared there was not enough research to 
support the safety of changing the deferral to one year.98  In 2012, HHS requested 
information to consider more suitable blood donation criteria for MSM.99  
Between 2012 and 2014, PHS received at least three more letters from Congress 
calling for a revision of the MSM ban.100 
B. After Three Decades, All We Have is a Shaky Start 
In November 2014, ACBTSA met again to discuss a possible revision.101  
The meeting concluded with the recommendation of a one-year deferral on MSM 
blood donation and a joint statement from AABB and ARC endorsing it.102  The 
 
Another Man (MSM) (June 15, 2010), available at 
http://www.aabb.org/advocacy/statements/Pages/statement061510.aspx.  
 97. See Diaz, supra note 12, at 140 (stating that the blood banks’ suggesting a one-year deferral); 
Bensing, supra note 11, at 487 (providing results of the vote). 
 98. See Goldberg, supra note 74, at 53 (quoting the Committee, “[w]hereas we believe that the current 
donor deferral policies are suboptimal in permitting some potentially high risk donations while preventing 
some potentially low risk donations, we find that currently available scientific data are inadequate to 
support change to a specific alternate policy”). 
 99. Diaz, supra note 12, at 143; see generally Request for Info (RFI) on Design of a Pilot Operational 
Study to Assess Alternative Blood Donor Deferral Criteria for Men Who Have Sex with Other Men 
(MSM), 77 Fed. Reg. 14801 (proposed Mar. 13, 2012), available at http://www.gpo.gov/fdsys/pkg/FR-
2012-03-13/html/2012-6091.htm. 
 100. See McAdam & Parker, supra note 10, at 53 (quoting Sen. Kerry’s 2012 letter stating that the 
deferral should be guided by “the science of today and not the myths of twenty years ago.”); see generally 
Letter from Sen. John Kerry et al., U.S. Congress, to U.S. Dept. of Health & Human Svcs. (Jun. 8, 2012), 
available at https://votesmart.org/public-statement/706449/letter-to-the-kathleen-sebelius-secretary-of-
health-and-human-services#.VgLnGSBViko; see generally Letter from Rep. Mike Quigley et al., U.S. 
Congress, to U.S. Dept. of Health & Human Svcs. (Aug. 1, 2013), available at 
http://www.warren.senate.gov/files/documents/Bicameral%20MSM%20Blood%20Ban%202013.pdf; 
see generally Letter from Sen. Elizabeth Warren et al., U.S. Congress, to U.S. Dept. of Health & Human 
Svcs. (Dec. 15, 2014), available at http://www.warren.senate.gov/files/documents/2014-12-
15_Letter_to_HHS.pdf. 
 101. ADVISORY COMM. ON BLOOD & TISSUE SAFETY & AVAILABILITY (ACBTSA) U.S. DEPT. OF 
HEALTH & HUMAN SVCS., FORTY-FIFTH MEETING AGENDA (2014), available at 
http://www.hhs.gov/ash/bloodsafety/advisorycommittee/acbtsa-2014-11-meeting-agenda.html. 
 102. Letter from Jay E. Menitove, M.D. to Asst. Sec. for Health, U.S. Dept. of Health & Human Svcs. 
(Dec. 19, 2014), available at 
http://www.hhs.gov/ash/bloodsafety/advisorycommittee/recommendations/nov2014-
recommendations.pdf (providing meeting recommendations from the Forty-Fifth Meeting of the 
ACBTSA, held Nov. 13-14, 2014); see generally Am. Ass’n of Blood Banks, Am. Blood Ctrs. & Am. 
Red Cross, J. Statement on ACBTSA Recommendation to Change MSM Deferral Policy (Nov. 2014), 
available at http://www.aabb.org/advocacy/statements/Pages/statement141114.aspx.  
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FDA looked to BPAC to provide scientific support for the change so BPAC held 
a meeting in early December to hear data on the matter.103 
In a long-awaited move, the FDA released a statement on December 23, 
2014 announcing it would recommend a revision to the MSM blood donor ban 
in the form of a one-year deferral, allowing men who have abstained from sex 
with another man in the past year to donate.104  The press release noted that the 
FDA had a responsibility to regulate blood safety and that it had consulted with 
its related agencies to review the scientific data available in considering the 
propriety of amending the ban.105  The FDA acknowledged the recommendation 
would align the MSM deferral period with other high-risk groups and that it was 
working to create a blood surveillance program that would “monitor the effect of 
a policy change and further help to ensure the continued safety of the blood 
supply.”106 
Despite years of controversy over the lifetime ban, the proposal sparked 
instant criticism.107  Some condemned the change as barely incremental, though 
others conceded most policies change only incrementally.108  Senator Tammy 
Baldwin remarked the new policy was still unscientific and pressed for one 
“based on individual risk factors.”109  Gay Men’s Health Crisis also called for a 
“risk-based . . . policy, regardless of sexual orientation or gender identity, and to 
stop perpetuating the stigma and discrimination.”110  The group explained that 
“requiring celibacy for a year is a de facto lifetime ban,” which perpetuates the 
 
 103. See BLOOD PRODUCTS ADVISORY COMM., MEETING MINUTES SUMMARY (Dec. 2, 2014), 
available at 
http://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/BloodVaccinesandOtherBiologi
cs/BloodProductsAdvisoryCommittee/ucm426205.htm (stating BPAC was called on by the FDA to 
advise on the “value of HIV incidence measures in blood donors that may be suitable for inclusion in a 
planned general blood safety monitoring effort based upon laboratory markers detected at the time of 
blood donation”); see BPAC ADVISORY COMM., MEETING ANNOUNCEMENT (Nov. 14, 2014), available 
at  http://www.fda.gov/AdvisoryCommittees/ucm419754.htm (stating in early December, BPAC would 
meet to “hear scientific data related to reconsideration of the current blood donor deferral policy” 
including presentations from ACBTSA’s November meeting”). 
 104. See generally Press Release, U.S. Food & Drug Admin, supra note 26. 
 105. Id. 
 106. Id. 
 107. See generally Holden, supra note 28; see Scheller & Almendrala, supra note 23 (stating 
“[Change] disappoint[ed] prominent gay rights groups and HIV/AIDS researchers, who called the 
yearlong waiting period medically unnecessary and unscientific”). 
 108. Sabrina Tavernise, F.D.A. Easing Ban on Gays, to Let Some Give Blood, NY TIMES (Dec. 23. 
2014) (stating the change was barely incremental); but see id. (quoting Sean Cahill, Director of Health 
Policy Research at the Fenway Institute, who stated incremental is okay). 
 109. See Holden, supra note 28(quoting Sen. Tammy Baldwin); see generally Press Release, Sen. 
Tammy Baldwin’s Statement Regarding FDA Announcement on Discriminatory Blood Donation Policy 
(Dec. 23, 2014), http://www.baldwin.senate.gov/press-releases/ustatement-on-hhs-announcement-on-
blood-donation-policy. 
 110. Holden, supra note 28(quoting Gay Men’s Health Crisis). 
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discrimination common to the AIDS epidemic because no such broad celibacy 
requirement is in place for heterosexuals.111  The American Civil Liberties Union 
and the Human Rights Campaign made similar statements.112  Lambda Legal 
agreed the revision should be backed by science and experience, rather than 
“fear, generalizations, and stereotypes,” and pointed out that available blood tests 
can identify “all known serious blood-borne pathogens” within less than two 
months of exposure so a longer deferral for anyone is unnecessary.113  Another 
industry commentator described the “overly broad” nature of the revision which 
would burden an entire population with no accounting for monogamy, safe sex 
practices, or medication which almost eliminates the risk of infection.114  
Almost exactly one year later, the FDA released its final guidance on the 
policy change.115  The accompanying press release noted the FDA considered 
alternative options, including risk-based assessment which it declined based on 
lack of available scientific data, and pledged it would continue to explore other 
policies assuming they are in accordance with its “responsibility . . . to maintain 
a high level of blood product safety.”116  The FDA website features a question 
and answer space for the new guideline and states that it considered public input 
before finalizing the guidance, but it seems not all voices were heard.117  In the 
days that followed, advocates again expressed their frustration at the 
discrimination, stigmatization, and lack of scientific basis for a one-year MSM 
 
 111. See id. (quoting Gay Men’s Health Crisis); but see Julie Zauzmer, FDA to Propose Altering Ban 
on Gay and Bisexual Men Who Want to Donate Blood, WASH. POST, Dec. 23, 2014, 
https://www.washingtonpost.com/national/health-science/fda-to-propose-lifting-ban-on-gay-and-
bisexual-men-who-want-to-donate-blood/2014/12/23/92af3734-8acd-11e4-9e8d-
0c687bc18da4_story.html (quoting Peter Marks, Deputy Dir. of the Ctr. for Biologics Evaluation & 
Research who said about half of the people excluded by the current MSM deferral could donate); but see 
id. (quoting Daniel Bruner, Dir. of Legal Services at Whitman-Walker Health, who also compared the 
proposed deferral to asking heterosexuals if they have had sex in the last year). 
 112. See Holden, supra note 28(quoting Ian Thompson, a legislative representative at the American 
Civil Liberties Union who reiterated that this policy amounted to de facto discrimination and quoting 
David Stacy, Government Affairs Dir. at the Human Rights Campaign, who agreed the revision was 
stigmatizing and based on orientation). 
 113. See Holden, supra note 28(quoting Scott Schottes at Lambda Legal). 
 114. See Zauzmer, supra note 111(quoting Daniel Bruner, Dir. of Legal Services at Whitman-Walker 
Health). 
 115. See generally Press Release, U.S. Food & Drug Admin., FDA Updates Blood Donor Deferral 
Policy to Reflect the Most Current Scientific Evidence and Continue to Ensure the Safety of the U.S. 
Blood Supply (Dec. 21, 2015), available at 
http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm478031.htm. 
 116. See id. 
 117. See FDA.GOV, 
http://www.fda.gov/BiologicsBloodVaccines/BloodBloodProducts/QuestionsaboutBlood/ucm108186.ht
m (last visited Jan. 29, 2016). 
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celibacy policy.118  A recent poll indicated that only 6% of people support the 
new guideline.119 
Notwithstanding the immense criticism, the FDA should be praised for 
finally addressing at least some problems with the original ban.120  The revision 
brings the policy in line with deferrals for other high-risk populations, as well 
some efforts of the international community.121  The change also allows for a 
small increase in blood donation, thus reducing the national shortage by an 
estimated 2%.122  Some commentators also suggest that the removal of the MSM 
lifetime ban on blood donation could prompt the FDA to consider changing the 
deferral periods for MSM organ and tissue donation, as well.123 
III.  SO CLOSE AND YET SO FAR: ARGUMENTS AGAINST THE AMENDED POLICY 
A. Administrative Avenues 
From the administrative law perspective, challenges to the lifetime deferral 
on MSM blood donation included both procedural attacks on enactment and 
substantive attacks that it would be “arbitrary and capricious” under judicial 
review.124  In light of the FDA’s final guidance, earlier procedural deficiencies 
are irrelevant.  This section will briefly outline the possible outcome of a 
substantive challenge to the new policy, then argue that the FDA has an 
 
 118. See Dominic Holden, New FDA Policy Relaxes Ban On Gay  
Men Donating Blood, BUZZFEED, (Dec. 21, 2015, 11:58 AM), 
http://www.buzzfeed.com/dominicholden/new-fda-policy-relaxes-ban-on-gay-men-donating-
blood#.xspVE9gOb (quoting officials from the National Gay Blood Drive, Walter Whitman Health, and 
the Human Rights Campaign; presidential candidate Martin O’Malley; Rep. Jared Polis D-CO; and Sen. 
Tammy Baldwin); see Press Release, Sen. Elizabeth Warren, Warren Joins Quigley, Lee, and Baldwin in 
Responding to FDA Policy Change to Blood Donor Deferral Policy for MSM (Dec. 22, 2015), available 
at http://www.warren.senate.gov/?p=press_release&id=1041. 
 119. See Brian Ries, FDA Eases Lifetime Ban on Blood Donations from Men Who Have Sex with Men, 
MASHABLE, (Dec. 21, 2015), http://mashable.com/2015/12/21/fda-gay-men-blood-
donations/#GonrwO.dEGqw (providing statistic of a poll conducted by YouGov). 
 120. See Holden, supra note 28(quoting Sen. Baldwin who praised the revision as “needed progress”). 
 121. Press Release, U.S. Food & Drug Admin., FDA Comm’r Margaret A. Hamburg’s Statement on 
FDA’s Blood Donor Deferral Policy for Men Who Have Sex with Men (Dec. 23, 2014), available at 
http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm427843.htm; see McAdam & 
Parker, supra note 10, at 65 (stating that Australia and the United Kingdom both have one-year deferral 
policies for MSM). 
 122. See Tavernise, supra note 108 (noting that the revision could raise the blood supply by 2%).  
 123. Anna Almendrala, Blood Donation Ban Is Only the First Barrier to Medical Equality For Gay 
Men, HUFFPOST, (Dec. 24, 2014, 8:05 PM), http://www.huffingtonpost.com/2014/12/24/gay-men-organ-
donors_n_6378658.html.  
 124. Casey, supra note 11, at 562 (discussing procedural attacks); Bensing, supra note 11at 502–07 
(discussing substantive attacks). 
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obligation to interpret its guidelines in a way that addresses, if not alleviates, 
potential constitutional issues.125 
1. Traditional Substantive Review 
Ordinarily, administrative procedure dictates that an agency is uniquely 
responsible for creating and giving meaning to its own guidelines and must 
adhere to the Administrative Procedure Act (“APA”) in doing so.126  The APA 
allows judicial review of an agency action for “[a] person suffering legal wrong 
. . .,or adversely affected or aggrieved by agency action.”127  Assuming arguendo 
that the FDA followed the proper procedure in enacting the guideline, an MSM 
prevented from donating blood could challenge it, if the guideline is entitled to 
judicial review.128  After determining it is entitled to judicial review, a reviewing 
court would use one of three standards to determine whether the guideline is 
permissible: arbitrary and capricious, de novo, or substantial evidence.129  The 
most appropriate standard would be arbitrary and capricious.130  In utilizing this 
standard, the court would evaluate “whether the [action] was based on a 
consideration of the relevant factors and whether there has been a clear error of 
judgment.”131  The court would also invalidate an action as arbitrary and 
 
 125. See generally Gillian E. Metzger, Ordinary Administrative Law as Constitutional Common Law, 
110 COLUM. L. REV. 479 (2010) (describing at length the link between administrative law and 
constitutional law, that a concept called the constitutional common law attaches to agency, and arguing 
its place in administrative law). 
 126. See McAdam & Parker, supra note 10, at 59 (stating that “[t]he APA governs the process by 
which federal agencies develop and issue regulations”); see also Bensing, supra note 11 at 502–503 
(explaining a court must find the action is final before proceeding to judicial review, as well as procedure 
for establishing whether a guidance is a final action and possible challenges the FDA could face because 
it relies on information from an advisory committee). 
 127. Bensing, supra note 11, at 502 (quoting the Administrative Procedure Act, 5 U.S.C. § 702 
(2006)). 
 128. Id. See Citizens to Preserve Overton Park, Inc. v. Volpe, 401 U.S. 402, 410 (1971) (stating that 
Administrative Procedure Act, 5 U.S.C. §701 provides agency action may be judicially reviewed if there 
is no statutory prohibition and if it has not been committed to agency discretion by law, and that 
“committed to agency action” means “statutes are written so broadly that there is no law to apply”). 
 129. See Bensing, supra note 11, at 502 (describing the procedure of judicial review); See also 
Citizens, 401 U.S. at 413 (explaining that to find the standard of review, Administrative Procedure Act, 5 
U.S.C. § 706 states that “agency action must be set aside if the action was ‘arbitrary, capricious, an abuse 
of discretion, or otherwise not in accordance with law’ or if the action failed to meet statutory, procedural, 
or constitutional requirements”); See Bensing, supra note 11, at 504 (explaining the scope of review with 
respect to formal and informal rulemaking). 
 130. Citizens, 401 U.S. at 414–15 (explaining the limited circumstances where the substantial evidence 
test or de novo review is appropriate); McAdam & Parker, supra note 10, at 59 (comparing the FDA 
guideline to the evaluation given to the action in Citizens to Preserve Overton Park, Inc. v. Volpe, 401 
U.S. 402 (1971)). 
 131. See Citizens, 401 U.S. at 415 (“Although this inquiry into the facts is to be searching and careful, 
the ultimate standard of review is a narrow one. The court is not empowered to substitute its judgment for 
that of the agency”). 
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capricious if the agency put forth “insufficient reasons for treating similar 
situations differently.”132  However, reviewing courts typically give significant 
deference to agencies and the FDA may get even greater deference because some 
agencies are considered experts in specialized issues.133   
The FDA’s revised policy is arbitrary and capricious because it does not 
provide adequate reasons for treating similar situations differently and violates 
the public health principle to “treat like health risks alike.”134  Under the original 
policy, all MSM, even those who practiced safe sex or were monogamous, were 
permanently deferred but their heterosexual partners were only deferred for one 
year and all other heterosexuals only deferred if they solicited sex for money.135  
This was criticized succinctly as “tolerating a wide range of risks associated with 
heterosexual sex while imposing a zero tolerance attitude toward MSM, 
regardless of the risk associated with individual behavior.”136  The amendment 
only partially alleviates this problem.  MSM who remain celibate for one year 
are now aligned with that of other high-risk groups, so the policy purports to treat 
at least some similar situations the same.137  But the FDA ignores the similarity 
between “high-risk” heterosexual behaviors like general promiscuity, which are 
not even questioned, let alone addressed, and the perceived high-risk of sexually 
active MSM.  These heterosexuals arguably present a higher risk than sexually 
active MSM because that group incudes those who are not actually at high risk.  
The FDA rests its justification for the disparity on the statistic that MSM are 
more likely to have HIV but takes that statistic at face value and obscures the 
actual risk of MSM, an act that is not risky in and of itself, as compared to the 
actual risks of heterosexual sexual behavior.  MSM are deferred for one year but 
heterosexuals are only deferred for one year if they have engaged in one specific 
risky sexual practice: prostitution.  Leaving this group unaddressed allows the 
FDA to ignore the principle of treating like health risks alike. 
A court may also consider an agency action irrational if the agency “entirely 
failed to consider an important aspect of the problem.”138  The FDA entirely fails 
to consider all relevant factors and important aspects of the HIV problem.  First, 
it does not account for the growing number of heterosexuals with HIV.  Almost 
thirty years to the day after the CDC published the original guidelines outlining 
 
 132. McAdam & Parker, supra note 10, at 61. 
 133. Id. at 660–661. 
 134. Belli, supra note 16, at 366. 
 135. Larkin, supra note 12, at 129 (explaining why MSM deferral is dissimilar to other deferrals); see  
Casey, supra note 11, at 556 (“The policy does not classify any heterosexual activity—including multiple, 
concurrent anonymous partners—as significantly high risk to warrant even temporary exclusion”). 
 136. Larkin, supra note 12, at 129. 
 137. See Press Release, U.S. Food & Drug Admin, supra note 115. 
 138. McAdam & Parker, supra note 10, at 61 (citing Motor Vehicle Mfrs. Ass’n v. State Farm Mut. 
Auto. Ins. Co., 463 U.S. 29, 43 (1983)). 
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homosexual and bisexual males as high-risk, it published another report stating 
that in 2009, 27% of HIV infections were attributed to heterosexual contact.139  
While MSM are statistically more likely to have HIV, the heterosexual 
population rate has been increasing steadily.  If heterosexuals possess 
approximately one-third of the risk in transmitting HIV, why are they freely 
permitted to donate with little accountability for their sexual history?  
Additionally, the FDA ignores the fact that AIDS disproportionally burdens 
African Americans of any sexual orientation by 21%.140  Second, the FDA fails 
to address data indicating that the chances of getting AIDS through blood 
transfusions are greater than through risky sex in the first place.141  The CDC’s 
website clearly states that for every 10,000 people exposed to AIDS, 92.5% of 
the infections will have come from a blood transfusion but only 1.49% of 
infections will have come from anal sex and only 1.61% from all sex practices 
by persons of any orientation.142  Despite this scientific data, the guideline singles 
out MSM-specific sexual practices but does not address any of these factors that 
are also relevant to protecting the blood supply. 
Administrative challenges permit a court to evaluate a guideline on its 
merits without reaching the question of constitutionality, if it is able.143  The court 
prefers to avoid constitutional challenges whenever possible.  No version of the 
MSM guideline has been challenged in court on any grounds but some 
foreshadowing of a discriminatory challenge, although in the context of 
geographic and national origin as a basis for deferral, arose at the 1990 BPAC 
meeting.144  One director at the Center for Biologics Evaluation and Research 
(“CBER”) stated that the “primary responsibility of the FDA is to assure the 
safety of the national blood supply. We are not a social service agency… [social 
injustice or discriminatory practice] issues lie outside the province of the FDA’s 
authority.”145  The FDA is commanded to protect the blood supply, yet as an 
 
 139. See CDC, HIV Infection Among Heterosexuals at Increased Risk, 62(10) Morbidity & Mortality 
Wkly Rep. 183, 183–88, Mar. 15, 2013, http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6210a2.htm. 
 140. AIDS.GOV, https://www.aids.gov/hiv-aids-basics/hiv-aids-101/statistics/ (last visited Sept. 26, 
2015). 
 141. See Casey, supra note 11, at 553 (providing the statistical likelihood of contracting AIDS through 
blood transmission and intercourse). 
 142. CDC.GOV, http://www.cdc.gov/hiv/policies/law/risk.html (last visited Sept. 26, 2015). 
 143. See Bensing, supra note 11, at 502 (explaining that administrative law is another avenue for 
redress to an injury, in additional to constitutional law); see Metzger, supra note 125, at 489–90 
(explaining that there are ways to avoid addressing some constitutional issues. For example, if court can 
do so because the APA already mandates a certain procedure or when “ordinary administrative law 
doctrines prohibit arbitrary agency decision-making has allowed the Court to avoid determining whether 
the Constitution requires agencies to issue certain standards”). 
 144. See Charlene Galarneau, Blood Donation, Deferral, and Discrimination: FDA Donor Deferral 
Policy for Men Who Have Sex with Men,  AM. J. OF BIOETHICS, Feb. 2010, at 29, 36 (explaining a history 
of the deferral and resulting stigmatization of the Haitian risk group). 
 145. Id. 
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agency it is not exempt from considering its policies in light of potential 
constitutional questions, meaning the FDA should put forth guidelines that avoid 
judicial invalidation should the court be forced to consider the question of 
constitutionality. 
2. Canon of Constitutional Avoidance 
All branches of government are guided by the Constitution and, as part of 
the executive branch, agencies have a “legally enforceable duty to avoid” 
infringing it, in addition to their responsibilities under the APA.146  There is a 
unique link between constitutional and administrative law because some 
administrative doctrines are created to meet constitutional requirements and 
“agencies are encouraged to take constitutional concerns seriously in their 
decision-making.”147  This means administrative law runs parallel to the idea of 
“constitutional common law,” as coined by Henry Monaghan, which refers to “a 
substructure of substantive, procedural, and remedial rules drawing their 
inspiration and authority from, but not required by, various constitutional 
provisions [and] subject to amendment, modification, or even reversal by 
Congress.”148  Constitutional common law finds an unacknowledged mooring in 
administrative law which has requirements under both the APA and the 
Constitution, although constitutional common law has been criticized as “judicial 
lawmaking” and the Supreme Court has downplayed the influence of the 
Constitution on judicial review.149  However, the constitutional gloss over 
administrative agencies generally lends credence to the idea that the FDA has 
somewhat of an obligation, similar to the court’s use of the canon of 
constitutional avoidance, to avoid reaching constitutional lines when creating 
guidelines that may face judicial review. 
In F.C.C v. Fox Television Stations, Inc., the Supreme Court rejected the 
argument that “agency decisions implicating constitutional liberties trigger more 
stringent arbitrary and capricious review.”150  Writing for the majority, Justice 
Scalia found “the canon of constitutional avoidance was an interpretive tool to 
be used only to construe ambiguous statutory language to avoid serious 
constitutional doubts.”151  He noted that no precedent required the Court to apply 
the canon to limit the scope of authorized action and that the APA distinguishes 
 
 146. Metzger, supra note 125, at 524. 
 147. See id. at 484 (describing the relationship between administrative and constitutional law). 
 148. See id. at 481 (explaining “constitutional common law” and pointing out the concept pervades 
administrative law). 
 149. See id. at 481, 483 (explaining criticisms of constitutional common law and the slight on the link 
between constitutional law and judicial review which was denounced in F.C.C v. Fox Television Stations, 
556 U.S. 502 (2009)). 
 150. Id. at 484. 
 151. F.C.C v. Fox Television Stations, 556 U.S. 502, 516 (2009). 
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judicial review of arbitrary and capricious action from judicial review of action 
that is patently unlawful, which would include unconstitutional action.152  He 
rejected the dissent’s idea of an agency requirement to “reconsider its policy in 
light of constitutional concerns” calling it “judicial arm-twisting.”153 
Despite the holding in Fox, the suggestion of such a divide between 
constitutional and administrative law may not be entirely warranted.154  The Fox 
Court attempted to separate the agency’s duty to avoid violating the Constitution, 
which is virtually undisputed, from the agency’s general obligation to consider 
constitutional gloss.155  However, that separation is impossible as a practical 
matter because agencies already consider the constitutional gloss to avoid actual 
constitutional violations, especially where the Constitution is unclear.156  Fox 
suggests constitutional law is precise, with a clear demarcation between what is 
and is not constitutional law yet administrative doctrines are actually grounded 
in both and sometimes agency action may fall somewhere on a continuum 
between needing judicial intervention and not being directly unconstitutional.157  
Much of constitutional law involves concepts that are imprecise, which affords 
agencies, including the FDA, wide latitude in determining whether its own 
policies comport with constitutional parameters.158  The Court’s slight on the 
relationship may permit a feeling of nominal accountability for agencies with 
respect to their “constitutional judgments,” possibly allowing agencies to fly 
under the radar in enacting policies that are not directly unconstitutional but 
would benefit from being “constitutionally inspired.”159  The real issue in Fox is 
whether courts should be able to use administrative law to force agencies to 
 
 152. Id. See Metzger, supra note 125, at 484 (stating “the only context in which constitutionality bears 
upon judicial review of authorized agency action is when a court determines the agency action is 
unconstitutional”). 
 153. Id. 
 154. See id (explaining that a strict separation between constitutional and administrative law is not 
correct). 
 155. See id. at 524 (explaining the Fox Court distinguished between duty to avoid violating the 
Constitution versus an obligation to “consider its norms and principles more generally”).   
 156. See id. (explaining that the Court tried to distinguish between a duty to avoid violating the 
Constitution versus consideration of the Constitution, generally). 
 157. See id. at 485, 516 (explaining that there is not always a clear line between what is governed by 
constitutional law and what is not but that administrative law is often rooted in both simultaneously which 
is what makes it constitutional common law and that because there is not clear divide, sometimes one 
given action both “implicate[s] constitutional values in a way that merits judicial response yet does not 
provide a sufficient basis for a court to hold the action unconstitutional or to preclude congressional 
revision of judicial determinations.”). 
 158. See Bensing, supra note 11, at 508 (noting that the imprecision of Constitutional law permits a 
wide range for agency interpretation). 
 159. See Metzger, supra note 125at 486, 505 (explaining that because the court often ignores the link 
between the Constitution and administrative law, agencies are not always clear as to what is required and 
courts do not enforce the requirements). 
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“consider constitutional concerns” but it does not necessarily follow that judicial 
enforcement is required simply by suggesting agencies have an obligation to 
consider constitutional parameters in agency action.160  The obligation is inferred 
from “government officials’ . . . independent duty to support” constitutional 
order.161 
If the court is unwilling to force the issue of constitutional consideration, 
the opposite  but possibly appropriate approach is the use of constitutional 
avoidance, which is widely embraced by the courts.162  When the Supreme Court 
hears any controversy, it must adhere to the canon of constitutional avoidance, 
meaning it must find a way to resolve the legal question before it without 
deciding whether the question violates the Constitution, if possible.163  In the 
administrative context, that means the Court will rely on the administrative 
parameters already in place in order to avoid reaching the constitutional 
question.164  The FDA should take cue from the Court and construct its guidelines 
in a way that avoids the Court having to reach the constitutional question, should 
the guidelines face judicial review.  Because the separation between 
administrative and constitutional law is not as wide as Justice Scalia suggested, 
“concern that a reviewing court may invoke the canon in lieu of [another test 
determining] deference may [incentivize] an agency to forgo broad assertions of 
authority or interpretations of ambiguous statutes” that would otherwise draw the 
agency toward the perpetually blurry lines that make up the parameters of the 
Constitution.165  In doing this, the agency gives up some deference to make 
policy but also averts unfavorable judicial review that could undermine its 
decisions altogether.166  The FDA should reevaluate its guideline so as not to 
implicate the Constitution because the current policy risks evaluation under 
 
 160. Id. at 524. 
 161. Id. at 522. 
 162. See id. at 520 (explaining that constitutional avoidance is a “vibrant” part of the statutory 
interpretation approach). 
 163. See Ashwander v. Tenn. Valley Auth., 297 U.S. 288, 347 (1936) (“The Court will not pass upon 
a constitutional question although properly presented by the record, if there is also present some other 
ground upon which the case may be disposed of. Thus, if a case can be decided on either of two grounds, 
one involving a constitutional question, the other a question of statutory construction or general law, the 
Court will decide only the latter”); See also Metzger, supra note 125, at 520–21 (explaining that court 
reliance on administrative laws rather than constitutional law is the equivalent of the cannon of 
constitutional avoidance but also that “judicial development of ordinary administrative law doctrines to 
address constitutional concerns is more contentious” occasionally sanctioned and rarely overtly 
condemned however, as in Fox, the Court hesitates “to use ordinary administrative law as mechanism to 
encourage administrative constitutionalism.”). 
 164. Metzger, supra note 125, at 520. 
 165. See id. at 499 (suggesting that if an agency believes a reviewing court may use the canon of 
constitutional avoidance instead of Chevron deference, it may draft less ambiguous statutes or broad 
assertions). 
 166. See id. (stating the agency gives up power to protect itself from judicial scrutiny). 
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constitutional standards that it may not survive.  If an MSM challenged the 
guideline, a court would necessarily have to attempt to decide the question before 
it without reaching the constitutional question but if it could not, it faces other 
problems explained below.  Yet, even if a guideline might pass constitutional 
muster, agencies should not disregard issues that draw it near a constitutional 
question in the first place.167   
However, actual constitutionality becomes less important if an agency can 
justify and explain its constitutional considerations in decision-making.  
“[C]areful explanation of how constitutional concerns were accommodated or 
why [they] are outweighed is all that an agency must supply.  It then becomes 
the courts’ responsibility to determine whether the agency’s decision accords 
with constitutional requirements.”168  In the context of the MSM guideline, the 
FDA might be required to explain the science they rely upon to justify the 
continued use of a policy that is so clearly discriminatory, which could pose 
problems explained below. 
Even without a requirement that an agency consider constitutional concerns 
or an incentive to avoid judicial review lest the Court overturn the agency action, 
decision-making in enacting guidelines should be inspired by the reaches of the 
Constitution.169  Congress gives agencies significant independent discretion in 
shaping national policy.170  Sometimes “taking constitutional values into account 
may change shape of federal regulation and make it less effective in achieving 
congressional regulatory goals but Congress might well accept a trade-off of 
regulatory effectiveness for greater protection of constitutional values.”171  
Congress gave the FDA, as an agency of HHS, power to protect the health of the 
nation but Congress has also made clear it disfavors the FDA’s revised MSM 
blood ban.  As shown by the statistics above, it is not even clear Congress has to 
trade effectiveness for a non-discriminatory policy.  A blood deferral policy 
based on screening questions and risky behavior would satisfy both goals of 
policy effectiveness and constitutional avoidance. 
But agencies should also want to embrace their influential role as leaders.172  
Agencies can exercise considerable influence in making polices that have 
 
 167. See id. at 525 (noting that even if the agency may win on a direct constitutional challenges does 
not mean they should abandon all constitutional concerns). 
 168. Id. at 526. 
 169. See id. at 497 (arguing that should be guided by the Constitution’s principles). 
 170. Id. at 522. 
 171. Id. at 523. 
 172. Id. at 497 (noting also that “ the constitutional law-administrative law interplay is one curtly 
dismissed in Fox and on other occasions, as well the Court displayed ambivalence about encouraging such 
administrative constitutionalism…[ but] link[sic] between [them] decision making surfaces with some 
regularity in judicial decisions and is often fostered by political branch enactments.”). 
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constitutional goals in mind.173  Some agencies, including the Equal Employment 
Opportunity Commission and the Federal Communications Commission, have 
already used their positions to positively influence areas like pregnancy 
discrimination and non-discriminatory licensee requirements, respectively.174  
This suggests the FDA, as a recognized leader, owes the public something 
beyond its congressionally mandated task; a duty to aim higher than the 
minimum requirement.  Rather than simply adjusting the ban based on “science,” 
the FDA should amend its guideline to affirmatively promote the values and 
address the concerns of recent jurisprudence on LGBTQ discrimination. 
B. Constitutional Complications 
Commentators also argue the new deferral for MSM blood donations is as 
discriminatory as the original and may violate some guarantees protected by the 
Constitution.  Both the Due Process Clause and the Equal Protection Clause of 
the Constitution are used to provide a framework to analyze possible 
discrimination, however the Due Process Clause is reserved for deprivations of 
a fundamental liberty or right and blood donation is unlikely to qualify as 
either.175 Therefore, this comment proceeds via challenge to the Equal Protection 
Clause. 
Although the ban unquestionably discriminated against homosexual men 
when it was enacted, and the new guideline likely does as well, traditional Equal 
Protection arguments have not gained traction because sexual orientation has 
never been considered a suspect or quasi-suspect class subject to elevated 
scrutiny against governmental discrimination.  This section argues that the 
FDA’s revision amounts to both de jure and de facto discrimination and that, 
although it would be analyzed under (and may pass) rational basis scrutiny 
because sexual orientation is not a suspect class, given the Court’s recent 
decisions and the pro-LGBTQ direction of the other government branches, the 
Court is likely to make sexual orientation a suspect or quasi-suspect class soon, 
which would raise the scrutiny level of government action and require a complete 
overhaul of the FDA’s new guideline. 
1. De Jure and De Facto Discrimination 
The Equal Protection Clause requires all persons similarly situated be 
treated alike and the cases decided in accordance with it provide guideposts for 
 
 173. Id. at 500. 
 174. Id. at 504. 
 175. See Morrison, supra note 35, at 2387 (stating that Due Process analysis requires infringement on 
a fundamental right). 
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analyzing differential treatment afforded to those persons.176  Government 
actions fall into two classifications: facially discriminatory (de jure) or facially 
neutral with unequal application (de facto).  If a government action is plainly 
discriminatory on its face, a plaintiff need not make any other showing before 
the action is evaluated.  If a government action is facially neutral but a plaintiff 
claims a discriminatory impact, that plaintiff will also need to show 
discriminatory intent or purpose before evaluation.177  To show discriminatory 
intent, the “challenged classification must single out a particular class for 
disadvantageous treatment and that such was motivated by discriminatory 
purpose.”178  “Discriminatory purpose implies the decision maker selected or 
reaffirmed a course of action at least in part because of, not merely in spite of, 
its adverse effects upon an identifiable group.”179  Proof is obtained from non-
exclusive factors like whether history “reveals a series of official actions taken 
for invidious purposes,” substantive “departure from normal procedure,” or 
legislative and administrative history of discrimination.180 
Both the original guideline and the revision to the MSM deferral result in 
de jure discrimination against MSM because the language of the guideline 
singles them out, although the FDA attempts to downplay the impact of the 
unambiguous language.  The FDA website states the policy is not discriminatory 
because it is “based on the documented increased risk of certain transfusion 
transmissible infections, such as HIV, associated with male-to-male sex and is 
not based on any judgment concerning the donor’s sexual orientation.”181  
Despite this self-serving statement, the FDA does make a judgment concerning 
sexual orientation, as illustrated by the 1992 memorandum and the BPAC 
meeting that preceded it.  At the meeting, the agency discussed changing the 
deferral period for MSM and their female sexual partners.182  Changing the 
deferral for female sexual partners but not MSM was justified as a “distinction 
between a person who themselves engaged in risky behavior versus persons who 
 
 176. Belli, supra note 16, at 347 (citing Cleburne, Texas v. Cleburne Living Ctr., Inc., 473 U.S. 432, 
439 (1985)) (“stating “The Equal Protection Clause […] commands that no State shall ‘deny to any person 
within its jurisdiction the equal protection of the laws,’ which is essentially a direction that all persons 
similarly situated should be treated alike.”); Morrison, supra note 35, at 2389 (noting that the Equal 
Protection Clause reaches equity in differential treatment). 
 177. See Belli, supra note 16, at 348–49 (explaining what is required and what evidence will show its 
existence). 
 178. Id. at 348–49. 
 179. Id. at 349. 
 180. Village of Arlington Heights v. Metro. Housing Dev. Corp., 429 U.S. 252, 265–68 (1977).  
 181. FDA.GOV 
http://www.fda.gov/BiologicsBloodVaccines/BloodBloodProducts/QuestionsaboutBlood/ucm108186.ht
m (emphasis added) (last visited Sept. 26, 2015). 
 182. See Galarneau, supra note 144, at 35 (stating that deferrals for both were considered at the 1992 
BPAC meeting). 
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have been sexual partners of members of a high-risk group.”183  When the 
committee also considered reducing the MSM deferral to one year, they were 
reminded of their earlier view that “persons who have ever had such high-risk 
behavior could potentially have it as a basis of a lifestyle choice.”184  BPAC 
retained the MSM deferral in 1992 on the basis of judgment about MSM as a 
lifestyle choice.  The revised guideline claims to be based entirely on scientific 
data, suggesting MSM is still viewed in the same light—that their lifestyle choice 
is risky—but despite this lifestyle choice, some blood donations are now 
acceptable because science can protect the blood supply enough to overcome 
them. 
This discussion at the meeting alternatively reflects de facto discrimination.  
The impact of the ban is clear but its intent and purpose is demonstrated in noting 
that historically, the ban has been motivated by fear and discrimination.185  With 
respect to de facto discrimination, proof in the form of a substantive departure 
may be relevant, “if the factors usually considered important by the decision-
maker strongly favor a decision contrary to the one reached.”186  As long as the 
MSM deferral has existed, the FDA has relied on the fact that the MSM group is 
statistically more likely to have HIV.  Although it now claims science allows it 
to move the deferral from a lifetime to one year, that statistic while mostly 
irrelevant is still true.  The blood tests the FDA relies upon have been in existence 
for years and can detect the presence of HIV in men who have had sex with men 
since last year or last month.  Although the latency period plays a role in length 
of deferral, risky behavior should be deferred rather than people who identify 
with a certain sexual orientation.  A factor that has continued to be important to 
the FDA is safety of the blood supply.  It now finds it safe to allow a small portion 
of MSM to donate blood but entirely ignores the risk factor presented by a group 
that can already give it almost without restriction: heterosexuals. 
2. The Scrutiny Level Should Be Elevated Beyond Rational Basis 
Equal Protection claims are reviewed under three standards of scrutiny: 
strict, intermediate, and rational basis.187  Rational basis is the lowest form of 
review for an Equal Protection challenge.188  Under rational basis review, 
“legislation is presumed to be valid and will be sustained if the classification 
 
 183. Id. 
 184. Id. 
 185. See id. at 36 (describing the history of the blood deferral as against Haitians). 
 186. Village of Arlington Heights, 429 U.S. at 267–68. 
 187. See McAdam & Parker, supra note 10, at 56; see id. at n.320 (explaining that strict scrutiny is 
the highest form of review and is reserved for suspect classifications like race, intermediate scrutiny is 
utilized to assess laws that implicate the quasi-suspect class gender, and all other legislation is reviewed 
under rational basis). 
 188. See Diaz, supra note 12, at 150 (stating that rational basis is the lowest standard of review). 
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drawn by the statute is rationally related to a legitimate government interest.”189  
Most government actions are presumed constitutional.190  Sufficient scholarly 
work exists evaluating the original MSM deferral under rational basis review.  
The revision does not change that analysis; the same arguments made against the 
lifetime deferral apply with equal force to the one-year deferral minus those that 
spoke to the inequality of the timeframe.  If the guideline is presented as a 
constitutional question, the Court may apply rational basis scrutiny because 
sexual orientation is not a class that automatically requires heightened scrutiny 
and the FDA relies on science to enact a guideline that relates to public health.  
Unless the Court found the scientific evidence the FDA relied on in perpetuating 
the ban was scientifically untenable, which it might for reasons discussed in Part 
III, C, the FDA could win.  However, the Court is also poised to increase the 
scrutiny level for discrimination on the basis of sexual orientation as evidenced 
by the recent social and legal changes with respect to LGBTQ rights and a 
challenge to the FDA’s one-year ban would not survive elevated scrutiny. 
a. The Possibility of Heightened Scrutiny Due to Animus 
The next official step on the scrutiny ladder is intermediate but between that 
and rational basis lies an unofficial level sometimes labeled “rational basis with 
bite.”191  Scrutiny beyond rational basis but not quite reaching the intermediate 
level has been found where the Court established “animus.”192  An exact 
definition of animus has never been clearly delineated by the Court but it has 
been described as a “bare congressional desire to harm a politically unpopular 
group” or demonstrated by “fear, stereotype, bias, or a simple desire to 
exclude.”193  Laws that reflect the latter grouping qualitatively “express, create, 
and enforce distinctions between social groups, tending to create a caste society” 
and both describe what the Equal Protection Clause is purported to protect 
 
 189. Belli, supra note 16, at 347 (citing City of Cleburne, TX v. Cleburne Living Ctr., Inc., 473 U.S. 
432, 440 (1985)). 
 190. See Susannah W. Pollvogt, Windsor, Animus, and the Future of Marriage Equality, 113 COL L. 
REV. SIDEBAR 204, 207 (2013) (stating that rational basis is extremely deferential to government action 
and presumes constitutionality). 
 191. See McAdam & Parker, supra note 10, at 56 (explaining levels of scrutiny); see generally 
Cleburne Living Ctr., Inc., 473 U.S. 432 (which explains that in order for a class to become one afforded 
more searching review than rational basis, it must show a constitutional interest at stake, the group must 
have immutable characteristics, and the group must be a discrete and insular minority, and it must lack 
political power); see Pollvogt, supra note 190, at 208 (explaining that rational basis with bite is a deviation 
from rational basis). 
 192. Id. at 206–08 (explaining the traditional two-tiered framework of Equal Protection Clause 
analysis and the instances where the Court has deviated and applied a standard between rational basis and 
strict scrutiny known as “rational basis with bite”.). 
 193. Id. at 208–09. 
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against.194  Evidence of animus may be direct or inferred which also reflects the 
distinction between de facto and de jure discrimination discussed above.195 
Lawrence v. Texas extended the idea first considered in Romer v. Evans, 
that homosexuals should be given greater protection under the Equal Protection 
Clause and that a heightened scrutiny level might be more appropriate.196  The 
Lawrence holding rested on the Due Process Clause but Justice O’Connor’s 
concurrence implicated the Equal Protection Clause and purported to deviate 
from rational basis to protect persons affected by a law that reached and burdened 
sexual orientation but did not make it an official class due heightened 
protection.197  More recently, in U.S. v. Windsor, Justice Kennedy spoke of 
animus and disparate treatment in the context of same-sex marriage, referring to 
variations of the word “dignity” eleven times in driving home the point that all 
persons seeking to get married should be viewed as equal under the law.198  He 
spoke of the dignity of same-sex couples, their families, and their marriages and 
scolded Congress for interfering with it, noting that discrimination was not just 
the effect of the statute but its very essence as demonstrated by House reports 
defending “traditional heterosexual marriage.”199  He also noted that “[t]he 
avowed purpose and practical effect of the law here in question was to impose a 
disadvantage, a separate status, and so a stigma . . . [was] made lawful.”200 
It is possible that if the FDA guideline were brought before the Court on 
the discrimination question, it could be evaluated under the same “rational basis 
with bite” standard.   The MSM one-year deferral burdens homosexual men as a 
class because it treats their behavior as different from other risky sexual 
practices.  It’s difficult to find “bare congressional desire to harm a politically 
unpopular group” because it does not come from Congress although it may 
 
 194. Id. at 209. 
 195. See id. (explaining that the Court may look to direct evidence or infer animus from the structure 
of the law or lack or legitimate interest). 
 196. Morrison, supra note 35, at 2389 (noting that starting with Romer v. Evans, 517 U.S. 620 (1996), 
homosexuals were considered a class and in Lawrence v. Texas, 539 U.S. 558 (2003), they were given 
marginally heightened protection). 
 197. See  Pollvogt, supra note 190, at 208 (explaining that in her concurring opinion in Lawrence, 
Justice O’Connor alluded to such an idea); see Lawrence, 539 U.S. at 580, 582 (“We have consistently 
held, however, that some objectives, such as ‘a bare . . . desire to harm a politically unpopular group,’ are 
not legitimate state interests… “When a law exhibits such a desire to harm a politically unpopular group, 
we have applied a more searching form of rational basis re- view to strike down such laws under the Equal 
Protection Clause.”  Then stating that the question is whether moral disapproval can be a legitimate state 
interest then stating that such grounds were insufficient under rational basis review). 
 198. United States v. Windsor, 133 S. Ct. 2675, 2689, 2692–94, 2696 (2013). 
 199. See id. at 2693 (stating that the history of enactment and the text of DOMA demonstrate 
interference with dignity). 
 200. Id. at 2691. 
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amount to that level of legislation as an administrative guideline.201  The one-
year deferral does amount to animus because it is partially driven by fear, 
stereotype, and bias.202  Although Windsor did not raise the scrutiny level 
afforded to sexual orientation either, this most recent departure from rational 
basis review to provide protection for homosexuals without committing to a 
higher level of scrutiny bolsters the foundation upon which the Court may build 
a shelter around sexual orientation.  The judicial concept of animus toward 
LGBTQ rights discussed in a multitude of cases suggests the direction of 
jurisprudence makes it suitable for LGBTQ to become a protected class in the 
near future. 
b. The Possibility of Heightened Scrutiny Due to Changing Legal 
Climate 
In the past five years, our country has seen monumental steps toward 
LGBTQ rights in the abandonment of major federal policies that differentiated 
groups based on sexual orientation.  In 2010, President Obama signed legislation 
to repeal “Don’t Ask, Don’t Tell,” the code that prohibited openly LGBTQ 
people from serving in the military.203  The military is certainly not a “social 
service agency” and yet issues of discrimination did not “lie outside of its 
province.”204 The very first objective of the law is to “determine any impacts to 
military readiness,” suggesting the primary goal in seeking to change its 
discriminatory policy is to evaluate any potential consequence to national 
security.205  The FDA’s primary objective in considering a change to its policy 
was also to maintain safety, but rather than removing its discriminatory 
characteristics, the FDA promoted safety by only allowing a small number of 
additional donations from those on the outermost fringes of “risky behavior,” but 
continues to categorizes people based on their private sexual choices.  In a formal 
statement addressing the repeal, the President stated he was proud to sign the 
legislation because it “bring[s] us closer to the principles of equality and fairness 
that define us as Americans.”206  This example of the executive branch changing 
 
 201. See Bensing, supra note 11, at 503 (explaining that an administrative guideline, while not 
generally considering binding or having the force and effect of law, can be construed as such if its “impact 
‘is sufficiently direct and immediate and has a direct effect on . . . day-to-day business’”).  
 202. Pulver, supra note 44, at 108; see Galarneau, supra note 144, at 29 (stating the MSM isn’t 
discriminatory due to blatant homophobia but partially driven by “stereotypes about sex, gender, and 
sexual behaviors”). 
 203. McAdam & Parker, supra note 10, at 55; Don’t Ask, Don’t Tell Repeal Act of 2010, Pub. L. No. 
111–321, 124 Stat. 3516. 
 204. See infra part III, section A, subsection 1, n. 139. 
 205. See infra part III, section A, subsection 1, n. 139. 
 206. Press Release, Office of the Press Secretary, Statement by the President on the Repeal of Don’t 
Ask, Don’t Tell (Sept. 20, 2011), available at https://www.whitehouse.gov/the-press-
office/2011/09/20/statement-president-repeal-dont-ask-dont-tell. 
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discriminatory laws regarding LGBTQ rights should signal the FDA, also a part 
of the executive branch, to reconsider its policy language to reflect the same 
principles.  Further, both the legislative and executive branches often compel 
“statutory and regulatory restrictions on administrative decision-making” that 
demonstrate their intention that agencies consider constitutional implications, 
further suggesting that the FDA be guided by the leader of its own branch of 
government as well as by the legislative branch.207 
Three years later, U.S. v. Windsor struck down a provision of the Defense 
of Marriage Act (“DOMA”) as unconstitutional because its definition of 
marriage served to undercut the dignity afforded to people in same-sex marriages 
and violated their liberty interest under the Due Process Clause.208  Then on June 
26, 2015, the Supreme Court held that all same-sex couples have a constitutional 
right to marriage in Obergefell v. Hodges.209  This opinion, also written by Justice 
Kennedy, focused on the institution of marriage and its meaning to anyone who 
seeks to enter into it.210  The holding is grounded in the Due Process Clause but 
Justice Kennedy cited earlier cases as evidence that due process and equal 
protection are often two sides of the same coin, stating that “rights implicit in 
liberty and rights secured by equal protection may rest on different precepts and 
are not always co-extensive, yet each may be instructive as to the meaning and 
reach of the other.”211  The opinion outlined how marriage has evolved, an 
evolution that has “strengthened, not weakened, the institution,” then analogized 
that evolution to treatment of the LGBTQ community, from the initial 
condemnation to the eventual public acceptance.212  Implicit in the language is a 
principle reminiscent of a different opinion Justice Kennedy took part in, 
Planned Parenthood of Pennsylvania v. Casey.  In considering the clear 
impropriety of earlier cases, Casey explained that in times of “national 
controversy,” “changed circumstances may impose new obligations.”213  In both 
 
 207. Metzger, supra note 125, at 502. 
 208. See generally United States v. Windsor, 133 S. Ct. 2675, 2693 (2013). 
 209. Obergefell v. Hodges, 135 S.Ct. 2584 (2015). 
 210. Id. 
 211. Id. at 2603. 
 212. Id. at 2596. 
 213. See Planned Parenthood of S.E. PA v. Casey, 505 U.S. 833, 861 (1992) (describing abortion as 
national controversy); see id. at 864 (explaining that when situations change, the court must reevaluate 
prior questions that have been decided); see id. at 863 (stating “[W]hile we think Plessy was wrong the 
day it was decided, we must also recognize that the Plessy Court’s explanation for its decision was so 
clearly at odds with the facts apparent to the Court in 1954 that the decision to reexamine Plessy was on 
this ground alone not only justified but required. West Coast Hotel and Brown each rested on facts, or an 
understanding of facts, changed from those which furnished the claimed justifications for the earlier 
constitutional resolutions. Each case was comprehensible as the Court’s response to facts that the country 
could understand, or had come to understand already, but which the Court of an earlier day, as its own 
declarations disclosed, had not been able to perceive.”). 
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Casey and Obergefell, Justice Kennedy reminded the Court that a change in 
understanding social issues may enable it to reconsider its harmful and 
stigmatizing precedent.  The message also serves to “characterize animus as 
something akin to unconscious bias as opposed to malicious intent” in that bias 
is often perpetuated by history rather than by something darker.214  In considering 
those judicial remarks, the FDA should take a hard look at the shadowy history 
of the MSM deferral and reconsider whether keeping a categorical ban on MSM 
behavior is the best way to preserve the safety of the blood supply or if there is 
an obligation to overhaul an entire deferral system that was predicated on 
discrimination. 
The combined impact of the statements on LGBTQ rights from the judicial 
branch, including the criticism of the legislative branch in Windsor, the President 
repealing “Don’t Ask, Don’t Tell,” and Congress’ continued support for a less 
discriminatory revision of the MSM blood donation deferral suggests the FDA 
must move toward a less discriminatory practice in order to conform with other 
areas of government.  While the revision from a lifetime deferral to a one-year 
deferral hides behind science for support, it was discriminatory when it was 
enacted and it is equally discriminatory now.  A meaningful revision to the policy 
must be grounded in safety but the FDA cannot ignore the inherent 
discrimination in light of the governmental direction with respect to LGBTQ 
rights, even if ameliorating social justice is “not in their province.” 
Although the FDA’s revision to the MSM deferral policy does not yet 
violate the Constitution as it does not relate to a liberty interest or affect a 
protected class due heightened scrutiny, it is difficult to say the FDA can ignore 
the current social climate or the potential for sexual orientation to become a 
protected class in the near future.  With changes to major laws affecting LGBTQ 
rights and the Supreme Court’s recent decisions on the issue, it is possible the 
Court will soon elevate the scrutiny afforded to sexual orientation and the laws 
that discriminate against LGBTQ to a level beyond rational basis and the FDA 
should be prepared. 
C. Synthetic Science Solves the Wrong Problem 
Scientific advancements in determining what causes HIV, as well as 
improved blood testing, have done much to prevent the spread of the disease 
through blood transfusion, making a lifetime deferral on MSM donating blood 
 
 214. Pollvogt, supra note 190, at 210–11 (“Justice Kennedy described the exclusion of same-sex 
couples from marriage as a mere artifact of a less enlightened time, which took on a more negative cast 
only in comparison to evolving notions of justice.  In so doing, Justice Kennedy characterized animus as 
something akin to unconscious bias as opposed to malicious intent.”). 
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unnecessary.215  The FDA acknowledged this when it announced that moving to 
a one-year deferral was scientifically supported.216  Although science technically 
supports the fact that moving from lifetime deferral to one year is safe, science 
does not support a celibacy requirement exclusively for MSM.  MSM are 
statistically more likely to have HIV but HIV is neither exclusive to nor caused 
by men having sex with other men.  Therefore, the FDA should consider the 
scientific arbitrariness of the classification and the scope of the ban should be 
revised rather than the length. 
When AIDS was first reported, it was thought to come from being gay.217  
Although that was disproved less than two years later, all versions of the 
guidelines have mentioned some variation of homosexual men as a high-risk 
category.218  Risky behavior such as unprotected sex, multiple partners, and 
sharing needles leads to the spread of AIDS.219  The act of men having sex with 
men is not inherently risky.220  The new policy prevents sexually active 
homosexual men from donating blood based on their sexual orientation rather 
than their actual risk to the blood supply—that isn’t science.  The agency forges 
a scientifically flawed distinction between MSM and heterosexual donors by 
categorizing and deferring donation based on one group’s risky behaviors but not 
the other group’s arguably riskier behaviors.221  The FDA recognized early on 
that “describing behavior is a better way to achieve public policy goals rather 
than using labels,” but never ameliorated the negative impact of its categorical 
distinctions.222  The oldest guidelines specified homosexual men as a high-risk 
category and newer ones addressed risky behavior of men having sex with other 
men generally, but all variations only address risky behavior of homosexual men 
and no one else.  Of course, protecting the blood supply from HIV is the biggest 
 
 215. McAdam & Parker, supra note 10, at 29–30 (describing the evolution of blood tests from ELISA 
and Western Blot to the nucleic acid test (“NAT”). 
 216. See Holden, supra note 28(quoting Peter Marks, Deputy Director of the FDA’s Center for 
Biologics Evaluation & Research “We would not recommend such a policy change if we didn’t think the 
safety of the blood supply would be maintained”). 
 217. See McAdam & Parker, supra note 10, at 23 (stating it was later confirmed that sexual orientation 
was not incident to the disease). 
 218. See Id. at 27 (outlining the language revisions by year). 
 219. But see Hochburg, supra note 12, at 238 (“Because of the risks associated with blood donors 
donating infected blood during the window period, thereby introducing HIV into the blood supply, 
“[e]xclusion of blood donors with an increased risk of HIV infection is considered an effective strategy to 
reduce the residual risk of HIV contamination [of the blood supply].”). 
 220. See Scheller & Almendrala, supra note 23 (quoting Dr. Wm. Kobler, spokesman for the Am. 
Med. Assn., “The lifetime ban on blood donation for men who have sex with men is discriminatory and 
not based on sound science”). 
 221. See McAdam & Parker, supra note 10, at 61 (noting that the distinction between heterosexual 
and MSM donors is untenable because AIDS comes from engaging in risky behaviors). 
 222. See Culhane, supra note 21, at 133–34 (noting the irony in the language change which did not 
alleviate the discrimination despite it moving toward risky behavior and away from broad categories). 
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priority, which makes it somewhat acceptable that the FDA maintained a strict 
donation policy on some variation of this category, at least for a while.  Yet, even 
if one concedes that “men who have had sex with another man even one time 
since 1977,” or even since last year, may have a statistically higher prevalence 
of AIDS than any other group, it is merely correlation, not causation.223 
The FDA stated it examined alternatives to the one-year deferral but the 
available scientific evidence best supported this option.224  The policy chosen has 
a demonstrated success rate in other countries with epidemiology similar to ours 
and was “based both on how the disease circulates in this country and on how 
donors here are screened.”225  Information for less than a twelve-month deferral 
was not available.226   The FDA noted that HIV is too prevalent in this country 
to completely lift the ban and move to risk-based screening like some 
countries.227  By the agency’s calculation, individualized screening would cause 
the risk of receiving infected blood to quadruple from its current likelihood of 
one in 1.5 million.228 
But in response to one advocacy group who protested the December 2014 
deferral announcement, the FDA is on record stating that self-assessment is 
unreliable, burdensome to donation centers, and offensive to donors.229  Self-
assessments are used to screen heterosexual donors so it does not make sense 
that they would be less reliable for MSM donors.230  Considering the blood 
shortage, it is hardly likely blood donation centers would be burdened by 
potentially eligible donors that might increase their workload.  The claim that 
self-assessment might be offensive arguably pales in comparison to the offense 
currently claimed by advocacy groups. 
The FDA claims to rely on science, but despite extensive research, the FDA 
admitted it “suffered from serious scientific deficiencies” and separately justified 
 
 223. See Morrison, supra note 35, at 2373 (stating that the gay community is still the leader in AIDS 
statistics). 
 224. See Press Release, U.S. Food & Drug Admin, supra note 115. 
 225. See Emma Margolin, FDA Ends Lifetime Ban On Blood Donations From Gay, Bisexual Men, 
MSNBC, (Dec. 21, 2015, 6:15 PM), http://www.msnbc.com/msnbc/fda-ends-lifetime-ban-blood-
donations-gay-bisexual-men (noting that the time-based deferral has been proven effective); see Donald 
G. McNeil Jr., F.D.A. Ends Ban, Allowing Some Blood Donations by Gay Men, NY TIMES, (Dec. 21. 
2015), http://nyti.ms/1S5snZ8 (citing Dr. Peter Marks’, deputy director of the FDA’s Center for Biologics 
Evaluation and Research explanation for the policy decision). 
 226. See Press Release, U.S. Food & Drug Admin, supra note 115. 
 227. See Holden, supra note 118. 
 228. See McNeil, supra note 225. 
 229. See Ed Coffin, The FDA Responds to Criticism of  
‘Loosening’ Ban on Blood Donations From Gay and Bi Men, HUFFPOST, (Dec. 31, 2014, 5:51 PM), 
http://www.huffingtonpost.com/ed-coffin/the-fda-responds-to-criti_b_6401460.html. 
 230. See id. 
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retaining the lifetime MSM policy based on data gaps as recently as 2007.231  
While this is not to say the FDA is not relying on current scientific data in 
promulgating the one-year deferral, its past performance should hardly garner 
public support of its provided justifications.  Further, its continued reliance on 
antiquated and illogical categorizations in the face of actual science and social 
progress sabotages their overall credibility.232 
In considering the grand scheme of protecting the nation’s blood supply, 
donor deferral is but one piece.233  Blood testing itself is another large 
component.  It should not be surprising that human error in handling the blood 
detracts from the overall safety of the supply.234  That includes both at the 
donation level and use level.  The related medical fields have utilized a concept 
called “purity in the bag,” which allows for more donors and the possibility of 
an increased blood supply by focusing on testing blood after it has been 
received.235  While it is not advantageous to let just anyone donate, the practice 
would still ensure the safety of the blood supply regardless of deferral reason. 
Currently, blood testing is so accurate that the possibility of anyone getting 
AIDS from a blood transfusion is small.236  Despite this, successful transmission 
of AIDS is actually more likely to occur through transfusion of infected blood 
than through intercourse with an infected person, so the chances of getting HIV 
from blood donated by MSM is actually infinitesimal.237  Regardless of the 
donor, at least one test can reveal an HIV infection in less than two weeks and 
all tests can detect blood-borne pathogens “within 45 days of exposure.”238  The 
National Institutes of Health (“NIH”) explained that positive HIV test results 
 
 231. See Galarneau, supra note 144, at 32–33 (describing the lack of justifiable data and analysis used 
by the FDA). 
 232. See id. 
 233. See Galarneau, supra note 144, at 30 (describing the FDA’s multi layer protection model). 
 234. See Jay P. Brooks, Using Basic Ethical Principles to Evaluate Safety Efforts in Transfusion 
Medicine, J. OF BLOOD TRANSFUSION, Nov. 2011, at 1, 4 (explaining that error rates in blood transfusion 
exist). See Belli, supra note 16, at 334–37 (explaining reasons for error rates). 
 235. See Brooks, supra note 234, at 1 (explaining the concept of “purity in the bag” as testing the 
blood once its been received). 
 236. Zauzmer, supra note  111 (quoting Peter Marks, deputy director of the FDA’s Center for 
Biologics Evaluation and Research, “[t]he chance of finding an HIV-contaminated unit in the blood 
supply, is 1 in 1.5 million”); See Hochburg, supra note 12, at 235 (“Direct blood contact is one of the most 
efficient, yet most preventable, forms of HIV transmission. In fact, an internationally recognized AIDS 
researcher asserts “the most successful single achievement in the prevention of HIV infection has been 
the drastic reduction in transfusion-acquired infection resulting mainly from effective screening of 
donated blood”). 
 237. See  Casey, supra note 11, at 553 (providing the risk of getting AIDS via intercourse as compared 
to getting AIDS thru a blood transfusion). 
 238. McAdam & Parker, supra note 10, at 49 (describing the use of “NAT” testing). See Holden, supra 
note 28(quoting Scott Schoettes, Lambda Legal senior attorney and director of the HIV Project that blood 
tests can detect AIDS in as little as 45 days). 
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may show up between six weeks and six months so the year long ban is aimed at 
peace of mind rather than a buffer zone for test results.239  Yet, the FDA has 
stated, “compelling scientific evidence [i]s not available . . . to support a change 
to a deferral period less than one year while still ensuring the safety of the blood 
supply,” double the time-frame provided by the NIH.240  But, the ACBTSA 
agreed the one-year deferral could “be looked at as a starting point” and CBER 
commented that the FDA would use the surveillance system to determine 
whether another revision could be considered.241  There seems to be a general 
consensus that even the one-year deferral is a time period chosen out of an 
abundance of caution but the agency is still focusing on the wrong problem.  The 
length of the ban is not what troubles advocates; it is the implications of stigma 
and a de facto ban for all men who continue to safely engage in the behavior the 
FDA is so adamant about singling out. 
Another consideration for protecting the blood supply is that our country is 
experiencing a blood shortage of crisis proportions.  “In September 2014 ABC 
News reported severe blood shortages in major cities including Los Angeles, St. 
Louis, Detroit, Philadelphia and Baltimore, with some hospitals reporting to 
being down to a single day’s supply.”242  The FDA claims it has a responsibility 
to maintain blood product safety but cannot ignore the fact that entirely removing 
the MSM ban could save approximately 657,000 lives, annually.”243 
The FDA promised it would continue to assess the policy as science 
progressed.244  If the one-year deferral is considered only a starting point, its 
trajectory should be to eliminate broad overgeneralizations and end with a 
guideline that focuses on meaningful questions about risky behavior, focused on 
individual evaluation with assessment for donor suitability.  One example would 
be to ask all donors, regardless of sexual orientation, “[i]n the past [two months], 
 
 239. See Zauzmer, supra note  111 (Anthony Fauci, director of the National Institutes of Health’s 
National Institute of Allergy and Infectious Diseases). 
 240. See Tavernise, supra note 108 (quoting Dr. Peter Marks, deputy director of the FDA’s Center for 
Biologics Evaluation and Research, “[a]t this time we simply do not have the evidence to suggest that we 
can go to a shorter period.”); see also generally Press Release, U.S. Food & Drug Admin, supra note 115 
(providing support for the same statement made last year). 
 241. See Brady Dennis, Government Could Ease 31-Year-Old Ban on Blood Donations from Gay Men,  
WASH. POST, (Nov. 29, 2014),  https://www.washingtonpost.com/national/health-science/government-
could-ease-31-year-old-ban-on-blood-donations-from-gay-men/2014/11/29/92ab8fae-7037-11e4-893f-
86bd390a3340_story.html (quoting Jay Menitove of ACBTSA); see Tavernise, supra note 108 (quoting 
Peter Marks of CBER). 
 242. Kelsey Louie & Sarah Kate Ellis, For Gay and Bi Blood Donors, New Rules but Same Ban, 
HUFFPOST, (Apr. 3, 2015, 8:07 PM), http://www.huffingtonpost.com/kelsey-louie/for-gay-and-bi-blood-
dono_b_7000510.html. 
 243. See Zack Ford, How The FDA’s Revised Blood Ban Caters to Religious Anti-Gay Beliefs, THINK 
PROGRESS, (May. 12, 2015, 4:46 PM), http://thinkprogress.org/lgbt/2015/05/12/3657901/gay-blood-
donation-celibacy/ (providing estimate). 
 244. See Press Release, U.S. Food & Drug Admin, supra note 115. 
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have you engaged in HIV risk behaviors — including condomless anal or vaginal 
sex, or shared drug-injecting paraphernalia — with an HIV-positive person or 
someone whose HIV status you did not know?”245  This would provide an 
arguably more accurate safety net for all persons.246  Advocates have called for 
this type of change as opposed to keeping a deferral based on “sexual orientation 
or gender identity” which perpetuates stigma and discrimination. 
The safety of moving to a risk-based screening has been documented 
abroad.  In 2001, Italy began using to an individualized, “risk-based 
questionnaire for donors, as opposed to a blanket deferral of MSM donors.”247  
They saw an increase in HIV-positive donations but found heterosexual donors 
caused that increase.248  In November 2015, France also reported an upcoming 
change to their MSM policy: MSM who have been celibate for one year may 
donate and MSM who have been monogamous or celibate “could donate after 
four months.”249  Moving to a risk-based assessment system here would also 
allow a significant increase in blood donations, would help to decrease the blood 
shortage, and would work to erase the continued belief that homosexual men are 
“contaminated.” 
Some may consider the additional costs and risk of error in screening so 
many donors as an obstacle, but those issues would arise with any increase in 
blood donation, as demonstrated in Italy.250  There is no way to combat an 
increased risk in error; any increase in donor pool logically increases the risk of 
error.  If ending the blood shortage is a priority, the FDA must be prepared to 
screen more blood and expect more errors.  However, with respect to the 
additional cost, the FDA is unable to “consider financial matters when making 
policy decisions.”251 
Risk, as a concept has been evaluated extensively and experts agree it is a 
“social, moral, economic and political concept as much as a scientific one.”252  
As one representative from the NIH predicted ten years ago, the MSM policy 
isn’t just about science, it’s a social justice problem and a fairness problem.253 
 
 245. Tim Murphy, Why Banning Gay Men from Donating Blood Is Dumb and Wrong, N.Y. MAG. 
(Dec. 2, 2014, 2:50 PM), http://nymag.com/daily/intelligencer/2014/12/banning-gay-men-from-donating-
blood-is-wrong.html. 
 246. Id. 
 247. McAdam & Parker, supra note 10, at 51 (use of blanket deferral); see Scheller & Almendrala, 
supra note 23 (noting Italy made this change in 2001). 
 248. McAdam & Parker, supra note 10, at 51 (noting the success in Italy’s policy). 
 249. See Holden, supra note 118 (providing information on France’s policy due to take effect Spring 
2016). 
 250. See id. (indicating Italy saw no change). 
 251. Larkin, supra note 12, at 132. 
 252. See Galarneau, supra note 144, at 34. 
 253. Id. at 35. 
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An assertion that the risk is acceptable and backed by science does not eliminate 
responsibility to justify it.254 
D. The Ban Goes Against Patient Autonomy and Social Justice 
Almost as long as the MSM deferral has been in place, the weight of 
scholarly authority has attacked it from administrative and constitutional law 
perspectives.  This Comment also evaluates the deferral from the bioethical and 
public health ethics standpoint.255 
The height of the civil rights movement brought recognition to ideas of 
dignity and equality, impacting philosophical study, which began to focus on 
practical ethics as opposed to abstract ideas about morality.256  Philosophers 
started to consider pragmatic issues like “abortion and euthanasia, the ethics of 
war and of capital punishment, and the allocation of scarce medical resources.”257  
This was one piece of a larger puzzle that created bioethics as a discipline.258  
The law powerfully informs “ethical reflection on moral responsibilities” which 
explains why lawmakers, government administrators, and a variety of 
professional organizations often seek bioethicists for consultation.259  Therefore, 
the principles of bioethics and the study of dignity and fairness are relevant to a 
discussion about the need for a safe blood supply and the use of a discriminatory 
policy to achieve it.  It has been argued that BPAC, and likely the FDA, lacked 
“the social, ethical, political, and economic expertise necessary to understand the 
full ramifications of the decisions it was making.”260  Although the statement 
refers to the very early deferral conversations, it is arguably still true.261 
There are various ethical paradigms in which to consider the breadth of 
issues that arise when considering the influence of bioethics on the law but this 
Comment will evaluate the MSM deferral under the Four Principles Approach, 
which employs the following duties: respect for autonomy, nonmaleficence, 
beneficence, and justice.262 
 
 254. Id. 
 255. See generally Morrison, supra note 35, at 2363 (2015). 
 256. See A COMPANION TO BIOETHICS 7 (Helga Kuhse & Peter Singer, eds., 2009) (tracing the history 
of Bioethics). 
 257. Id. 
 258. Id. 
 259. See Tom L. Beauchamp & James F. Childress, PRINCIPLES OF BIOMEDICAL ETHICS 40 (4th ed. 
1994) (explaining that the law is “a significant source for ethical reflection on moral responsibilities.”); 
see A COMPANION TO BIOETHICS, supra note 238, at 7 (“government commissions, law reform bodies, 
and professional organizations”). 
 260. See Galarneau, supra note 144, at 31. 
 261. Id. (explaining that the critique is still relevant). 
 262. See Gwendolyn P. Quinn, et al., Preserving the Right to Future Children: An Ethical Case 
Analysis, 12AM. J. OF BIOETHICS 6, 40 (2012) (quoting Beauchamp & Childress); see also Janet L. Dolgin 
& Lois L. Shepard, BIOETHICS AND THE LAW 20 (Aspen Publishers, 2005). 
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1. Respect for Autonomy: “Otherness” 
The first pillar of bioethics describes the idea of choice and one’s ability to 
make certain choices for himself.263  Setting aside the question of whether being 
homosexual is a choice or an innate and immutable characteristic, engaging in 
homosexual behavior is a choice.  A blood donation deferral category that singles 
out men who choose to engage in homosexual behavior is one of many ways the 
government acts to question the legitimacy of same-sex relations and the choice 
to engage in them.264  Judicial precedent disfavors that governmental propensity 
in the context of continued oppression of people who choose to engage in 
homosexual acts or marry someone of the same sex.265  In Obergefell, Justice 
Kennedy noted that the liberty contemplated by the Due Process Clause 
“extend[s] to certain personal choices central to individual dignity and 
autonomy, including intimate choices that define personal identity and 
beliefs.”266  The very holding of Obergefell rests on notions of autonomy and the 
freedom to engage in certain acts that are considered a fundamental right.267  To 
be sure, there is no fundamental right to donate blood but there is a right to have 
the government respect one’s autonomy and at the very least, notions of 
administrative constitutionalism instruct agencies to consider issues like 
discrimination.268  Continued use of this particular deferral language is another 
avenue for the government to attempt to control disfavored behavior.   
Discouraging autonomy calls to mind the notion of “otherness” which 
occurs when those of “privilege and power” are called on to define 
discrimination to the exclusion of anyone else.269 This creates an “us” versus 
“them” scenario which contributes to a backhanded loss of autonomy.  No one 
wants to be excluded from the “in” crowd so to avoid the “otherness”, people 
who otherwise would not are forced to hide their true identity. 
A second consideration is that the blood donor questionnaire itself assumes 
a “gender binary” or “an understanding of gender that classifies all persons as 
male or female and ignores persons who identify otherwise.”270  Again, setting 
aside the question of whether that sense of self-identity is something that can be 
altered, not all people simply identify as male or female, which can be confusing 
in the blood donation context.  This results in burdening people in a certain 
 
 263. Quinn, supra note 262, at 39 (quoting Beauchamp & Childress). 
 264. See Murphy, supra note 245. 
 265. See generally Obergefell v. Hodges, 135 S.Ct. 2584 (2015); see generally Romer v. Evans, 517 
U.S. 620 (1996). 
 266. Obergefell v. Hodges, 135 S.Ct. 2584 (2015). 
 267. See generally id. 
 268. Nancy Leong, Making Rights, 92 B.U.L. REV. 405, 415–16 (2012). 
 269. See Fisher & Schonfeld, supra note 6, at 41 (describing the concept of “otherness”). 
 270. See Galarneau, supra note 144, at 34. 
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category with a sense of “otherness” due to choices they have made about their 
gender.271  Further, without considering the actual number of homosexual males 
infected with HIV, the guideline burdens the entire group by grouping risky 
donors with safe ones.  The new blood donation guideline perpetuates problems 
of gender binary, exclusion, and government challenge to homosexual practices 
and conflicts with the ideas of autonomy.  
2. Nonmaleficence: Moral Panic Techniques 
The second pillar of the bioethical framework is maleficence; the idea that 
it is unjust to harm or inflict suffering on others.272  One problem with the 
continued use of homosexual male behavior as a deferral indicator is what it 
implies.  In one example, it was noted that monogamous homosexual men are 
barred but promiscuous heterosexuals are not, which “support[s] a longtime, ugly 
belief that gay men are in some sense contaminated.”273  Others assert that 
because homosexuality was historically classified as a mental disorder and 
people still find homosexuals to be ill-omened, the lifetime ban is a way to 
repress homosexuality using science to instill fear.274 
The revision lifts the lifetime ban in favor of a one-year deferral but because 
it functions as a de facto lifetime ban, the effects are the same.  Whether there is 
a way to quantitatively say that people believe homosexual men are contaminated 
or have a mental disorder, the FDA deferral acts to perpetuate that belief.  The 
simple act of singling them out without more than an unjustified reliance on 
science perpetuates a “moral panic.”  A moral panic is defined as “a method of 
placing a social issue in terms of an illness. A panic links one suspect thing with 
one definitely bad thing, which gives the message that the suspect thing must 
actually be bad.”275  Here, the deferral works to keep HIV synonymous with 
homosexual males, perpetuating the fallacy that they are more closely related 
than is actually correct.276 
A second justification on which the FDA may implicitly rely is the history 
of HIV impact on hemophiliacs.277  Hemophiliacs receive regular blood 
transfusions and were deeply and tragically affected by the lack of early 
information about HIV.278  Much of the blame fell on those who delayed ensuring 
 
 271. Fisher & Schonfeld, supra note 6, at 41. 
 272. Quinn, supra note 262, at 40. 
 273. See Murphy, supra note 245, at 228. 
 274. See Klugman, supra note 4, at 46. 
 275. See id. at 47. 
 276. See id. 
 277. See Caplan, supra note 83, at 2 (stating “the history of people suffering hemophilia” and that it 
“shapes the ongoing exclusion of gay men.”). 
 278. Id. 
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it was kept out the blood supply upon which this population so heavily relies.279  
Due to criticism of the way the situation was handled, regulators act with extreme 
caution.280  Some compare using, as a basis for the blood donor deferral, the 
catastrophic consequence that HIV had on the hemophiliac population to the way 
the Tuskegee Study and the Holocaust underlie the field of human 
experimentation, which could be overstating the impact for effect.281  Yet, 
hemophiliac safety alone cannot be used to justify mistreatment of MSM. 
3. Beneficence: Ideas of Civil Duty 
The bioethical principle of beneficence articulates the idea of “promoting 
good.”282  The revised FDA ban deprives an entire class of persons from 
engaging in what some consider a civic duty: the opportunity to engage in the 
altruistic act of donating blood to save a life.  Some men find a way to “beat the 
system” and lie on the blood bank questionnaire, just to have the ability to help 
those in need.283  Many homosexual men did just that after the World Trade 
Center attacks.284  The FDA recognizes that people want to help yet they cling to 
the stated obligation that safety is paramount.285  This is a “classic framing of 
ethical dilemmas in public health: a collective good . . . is posited as in conflict 
with the interests or rights of individuals.”286  In this case “donor rights to give 
blood and recipient rights to receive safe blood” are set up as necessarily 
opposing views, preventing any solution for both goals to be achieved.287  Rather 
than promote good, the deferral policy constrains it. 
 
 279. Id. (stating “the blame for the deaths of so many who require blood products was placed on those 
who did not react quickly enough to insure that HIV infected donors were kept out of the ranks of donors”). 
 280. Id. (stating “the legacy of the devastation of the hemophiliac community in the U.S. and other 
nations played a huge role in making regulators very nervous about relaxing standards”). 
 281. Id.; see Culhane, supra note 21, at 29 n.5. 
 282. Quinn, supra note 262, at 40. 
 283. See Murphy, supra note 245. 
 284. See id.; see also Brady Dennis, Government Could Ease 31-Year-Old Ban on Blood Donations 
From Gay Men, WASH. POST, (Nov. 29, 2014), https://www.washingtonpost.com/national/health-
science/government-could-ease-31-year-old-ban-on-blood-donations-from-gay-
men/2014/11/29/92ab8fae-7037-11e4-893f-86bd390a3340_story.html (quoting Ryan James Yezak of the 
National Gay Blood Drive, “The evidence is there; they’re just being cautious about implementing it . . . 
[But] we will get to where we want to be. . . . People want to serve their country. They want to do this 
thing that other humans partake in. Not being able to do this is wrong.” and Glenn Cohen, “The moral 
compass has shifted,” “We got rid of ‘Don’t Ask, Don’t Tell.’ You can shed your own blood for the 
country [if you’re gay]. But you can’t donate your blood to your fellow man? A lot of people take that as 
a second-class citizenship status.”). 
 285. See Galarneau, supra note 144, at 31 (quoting, “while appreciative…”). 
 286. See id. 
 287. See id. 
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4. Justice-Language 
The last pillar of bioethics focuses on fairness.288  Discrimination, or the 
unfair treatment of a group, is the ultimate injustice.289  “Social justice requires 
not the melting away of differences but promoting respect for group differences 
without oppression.”290  Through the power of language, the deferral revision 
reinforces injustice in two ways.  Much like the use of moral panic techniques, 
subtle use of language reinforces stigmatization.291 
First, blood donation centers “have developed a metaphor that giving blood 
makes one morally virtuous.”292  The implied alternative is that people who do 
not may be “morally suspect” or defective in some way, whether physically or 
in a social sense of not valuing life enough to donate blood to support it.293  
Although the blood donation industry fought to change the policy, they are 
constrained by the FDA through licensing and can only accept donations within 
FDA parameters. 
Second, the FDA’s change in terminology through the years reflects at least 
a slight move away from sexual orientation and toward risky behavior.294  
Despite this, their continued singling out approved donors based on sexual 
orientation rather than actual risk perpetuates the stigma that advocates have been 
trying to overcome since the ban was enacted.  Removing the lifetime deferral to 
include at least some MSM donors subtly reflects its acknowledgement of 
original overinclusiveness but it does not go far enough. 
 CONCLUSION 
Although the move from a lifetime deferral to a one-year ban is a step in 
the right direction, it still acts as a de facto lifetime ban on most men in the MSM 
category.  The new policy will allow more homosexual men to donate, increasing 
the blood supply, but this amendment to the deferral category continues to hold 
the MSM population under unnecessary scrutiny in light of scientific, legal, and 
social advancements.  The FDA engages in a mindset that if a MSM continues 
to engage in risky behavior, he should be deferred. While the new policy brings 
MSM in line with other groups designated high-risk, the whole deferral system 
 
 288. Quinn, supra note 262, at 40. 
 289. See Galarneau, supra note 144, at 32 (describing discrimination as injustice). 
 290. See id. at 37. 
 291. See Klugman, supra note 4, at 47 (“Whether its purposeful or just part of systemic subconscious, 
words have an effect on people’s perceptions and opinions.”). 
 292. See id. 
 293. See id. at 46. 
 294. See Goldberg, supra note 74, at 50 (explaining that until 1986, “categorizations focused on sexual 
orientation” and were changed to emphasize behavior); see Galarneau, supra note 144, at 30 (explaining 
the FDA recognized “HIV risk had a greater association with sexual behavior than with sexual identity.”). 
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should be dismantled in favor of actual risk-based screening rather than resting 
on statistical likelihood of risk, especially because the categories used to identify 
those at high-risk are both overinclusive (including men who are monogamous) 
and underinclusive (excluding heterosexuals who engage in risky behavior).  The 
only fair and viable solution is to move away from categorical screening and 
toward risk-based screening.  
